المؤلفون: V. V. Kalyuzhin, A. T. Teplyakov, I. D. Bespalova, E. V. Kalyuzhina, G. E. Chernogoryuk, N. N. Terentyeva, E. V. Grakova, K. V. Kopeva, V. Yu. Usov, N. P. Garganeeva, I. K. Livshits, I. V. Petrova, T. V. Lasukova, В. В. Калюжин, А. Т. Тепляков, И. Д. Беспалова, Е. В. Калюжина, Г. Э. Черногорюк, Н. Н. Терентьева, Е. В. Гракова, К. В. Копьева, В. Ю. Усов, Н. П. Гарганеева, И. К. Лившиц, И. В. Петрова, Т. В. Ласукова

المصدر: Bulletin of Siberian Medicine; Том 22, № 3 (2023); 98-109 ; Бюллетень сибирской медицины; Том 22, № 3 (2023); 98-109 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2023-22-3

مصطلحات موضوعية: посттрансляционная модификация, diastolic heart failure, left ventricle, diastolic dysfunction, mechanisms, endosarcomeric cytoskeleton, titin, alternative splicing, post-translational modification, диастолическая сердечная недостаточность, левый желудочек, диастолическая дисфункция, механизмы, эндосаркомерный скелет, титин, альтернативный сплайсинг

وصف الملف: application/pdf

Relation: https://bulletin.ssmu.ru/jour/article/view/5315/3443; https://bulletin.ssmu.ru/jour/article/view/5315/3462; Nazário Leão R., Marques da Silva P. Diastolic dysfunction in hypertension. Hipertens. Riesgo Vasc. 2017;34(3):128−139. DOI:10.1016/j.hipert.2017.01.001.; Samuel T.J., Beaudry R., Sarma S., Zaha V., Haykowsky M.J., Nelson M.D. Diastolic stress testing along the heart failure continuum. Curr. Heart Fail. Rep. 2018;15(6):332−339. DOI:10.1007/s11897-018-0409-5.; Bayes-Genis A., Bisbal F., Núñez J., Santas E., Lupón J., Rossignol P. et al. Transitioning from preclinical to clinical heart failure with preserved ejection fraction: a mechanistic approach. J. Clin. Med. 2020Apr.13;9(4):1110. DOI:10.3390/jcm9041110.; Ge H. Is diastolic dysfunction a new windsock in the risk stratification of patients with coronary heart disease? Int. J. Cardiol. 2022Jan.1;346:103−104. DOI:10.1016/j.ijcard.2021.11.037.; Bertacchini F., Agabiti Rosei C., Buso G., Cappellini S., Stassaldi D., Aggiusti C. et al. Subclinical HMOD in hypertension: left ventricular diastolic dysfunction. High Blood Press. Cardiovasc. Prev. 2022Nov.10. DOI:10.1007/s40292-022-00548-z.; Zhou D., Yan M., Cheng Q., Feng X., Tang S., Feng Y. Prevalence and prognosis of left ventricular diastolic dysfunction in community hypertension patients. BMC Cardiovasc. Disord. 2022Juny13;22(1):265. DOI:10.1186/s12872-022-02709-3.; Cianciulli T.F., Saccheri M.C., Papantoniou A., Méndez R.J., Gagliardi J.A., Prado N.G. et al. Use of tissue doppler imaging for the early detection of myocardial dysfunction in patients with the indeterminate form of Chagas disease. Rev. Soc. Bras. Med. Trop. 2020Feb.21;53:e20190457. DOI:10.1590/0037-8682-0457-2019.; Echeverría L.E., Gómez-Ochoa S.A., Rojas L.Z., García-Rueda K.A., López-Aldana P., Muka T. et al. Cardiovascular biomarkers and diastolic dysfunction in patients with chronic chagas cardiomyopathy. Front. Cardiovasc. Med. 2021Nov.29;8:751415. DOI:10.3389/fcvm.2021.751415.; Saraiva R.M., Mediano M.F.F., Quintana M.S.B., Sperandio da Silva G.M., Costa A.R., Sousa A.S. et al. Two-dimensional strain derived parameters provide independent predictors of progression to Chagas cardiomyopathy and mortality in patients with Chagas disease. Int. J. Cardiol. Heart Vasc. 2022Jan.10;38:100955. DOI:10.1016/j.ijcha.2022.100955.; Калюжин В.В., Кулаков Ю.А. Соотношения вегетативных, эмоциональных и соматических нарушений при хроническом описторхозе. Клиническая медицина. 1996;74(6):27−29.; Хардикова С.А., Берендеева Е.П., Калюжин В.В., Белобородова Э.И. Диастолическая дисфункция левого желудочка у больных псориазом на фоне хронического описторхоза до и после антигельминтной терапии. Клиническая медицина. 2009;87(10):29−32.; Калюжин В.В., Тепляков А.Т., Рязанцева Н.В., Вечерский Ю.Ю., Хлапов А.П., Колесников Р.Н. Диастола сердца. Физиология и клиническая патофизиология. Томск: Изд-во ТПУ, 2007: 212.; Ferreira-Martins J., Leite-Moreira A.F. Physiologic basis and pathophysiologic implications of the diastolic properties of the cardiac muscle. J. Biomed. Biotechnol. 2010;2010:807084. DOI:10.1155/2010/807084.; Janssen P.M.L. Myocardial relaxation in human heart failure: Why sarcomere kinetics should be center-stage. Arch. Biochem. Biophys. 2019;661:145−148. DOI:10.1016/j.abb.2018.11.011.; Драпкина О.М., Кабурова О.М. Диастолическая сердечная недостаточность: механизмы развития и перспективы воздействия на них. Журнал сердечная недостаточность. 2012;13(5/73):310−316.; Калюжин В.В., Тепляков А.Т., Калюжин О.В. Сердечная недостаточность. М.: Медицинское информационное агентство, 2018:376.; Лакомкин В.Л., Абрамов А.А., Студнева И.М., Уланова А.Д., Вихлянцев И.М., Просвирнин А.В. и др. Ранние изменения энергетического метаболизма, изоформного состава и уровня фосфорилирования титина при диастолической дисфункции. Кардиология. 2020;60(2):4−9. DOI:10.18087/cardio.2020.3.n531.; Bull M., Methawasin M., Strom J., Nair P., Hutchinson K., Granzier H. Alternative splicing of titin restores diastolic function in an HFpEF-like genetic murine model (TtnΔIAjxn). Circ. Res. 2016;119(6):764−772. DOI:10.1161/CIRCRESAHA.116.308904.; Gevaert A.B., Kataria R., Zannad F., Sauer A.J., Damman K., Sharma K. et al. Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart. 2022;108(17):1342−1350. DOI:10.1136/heartjnl-2021-319605.; Loescher C.M., Hobbach A.J., Linke W.A. Titin (TTN): from molecule to modifications, mechanics, and medical significance. Cardiovasc. Res. 2022;118(14):2903−2918. DOI:10.1093/cvr/cvab328.; Zhou Y., Zhu Y., Zeng J. Research update on the pathophysiological mechanisms of heart failure with preserved ejection fraction. Curr. Mol. Med. 2023;23(1):54−62. DOI:10.2174/1566524021666211129111202.; Van der Velden J., Stienen G.J.M. Cardiac disorders and pathophysiology of sarcomeric proteins. Physiol. Rev. 2019;99(1):381−426. DOI:10.1152/physrev.00040.2017.; Crocini C., Gotthardt M. Cardiac sarcomere mechanics in health and disease. Biophys. Rev. 2021;13(5):637−652. DOI:10.1007/s12551-021-00840-7.; Knight W.E., Woulfe K.C. Dysfunctional sarcomeric relaxation in the heart. Curr. Opin. Physiol. 2022;26:100535. DOI:10.1016/j.cophys.2022.100535.; Martin A.A., Thompson B.R., Hahn D., Angulski A.B.B., Hosny N., Cohen H. et al. Cardiac sarcomere signaling in health and disease. Int. J. Mol. Sci. 2022;23(24):16223. DOI:10.3390/ijms232416223.; Rosas P.C., Solaro R.J. Implications of S-glutathionylation of sarcomere proteins in cardiac disorders, therapies, and diagnosis. Front. Cardiovasc. Med. 2023Jan.24;9:1060716. DOI:10.3389/fcvm.2022.1060716.; Kass D.A., Bronzwaer J.G., Paulus W.J. What mechanisms underlie diastolic dysfunction in heart failure? Circ. Res. 2004;94(12):1533−1542. DOI:10.1161/01.RES.0000129254.25507.d6.; Rosas P.C., Liu Y., Abdalla M.I., Thomas C.M., Kidwell D.T., Dusio G.F. et al. Phosphorylation of cardiac myosin-binding protein-C is a critical mediator of diastolic function. Circ. Heart Fail. 2015;8(3):582−594. DOI:10.1161/CIRCHEARTFAILURE.114.001550.; Sheng J.J., Feng H.Z., Pinto J.R., Wei H., Jin J.P. Increases of desmin and α-actinin in mouse cardiac myofibrils as a response to diastolic dysfunction. J. Mol. Cell. Cardiol. 2016;99:218−229. DOI:10.1016/j.yjmcc.2015.10.035.; Valero-Muñoz M., Saw E.L., Hekman R.M., Blum B.C., Hourani Z., Granzier H. et al. Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF). Front. Cardiovasc. Med. 2022Aug.25;9:966968. DOI:10.3389/fcvm.2022.966968.; Li N., Hang W., Shu H., Zhou N. RBM20, a therapeutic target to alleviate myocardial stiffness via titin isoforms switching in HFpEF. Front. Cardiovasc. Med. 2022Jun.16;9:928244. DOI:10.3389/fcvm.2022.928244.; Lamber E.P., Guicheney P., Pinotsis N. The role of the M-band myomesin proteins in muscle integrity and cardiac disease. J. Biomed. Sci. 2022;29(1):18. DOI:10.1186/s12929-022-00801-6.; Gilbert G., Demydenko K., Dries E., Puertas R.D., Jin X., Sipido K. et al. Calcium signaling in cardiomyocyte function. Cold Spring Harb. Perspect. Biol. 2020;12(3):a035428. DOI:10.1101/cshperspect.a035428.; Denniss A.L., Dashwood A.M., Molenaar P., Beard N.A. Sarcoplasmic reticulum calcium mishandling: central tenet in heart failure? Biophys. Rev. 2020;12(4):865−878. DOI:10.1007/s12551-020-00736-y.; Benitah J.P., Perrier R., Mercadier J.J., Pereira L., Gómez A.M. RyR2 and calcium release in heart failure. Front. Physiol. 2021;12:734210. DOI:10.3389/fphys.2021.734210.; Rouhana S., Farah C., Roy J., Finan A., Rodrigues de Araujo G., Bideaux P. et al. Early calcium handling imbalance in pressure overload-induced heart failure with nearly normal left ventricular ejection fraction. Biochim. Biophys. Acta Mol. Basis Dis. 2019;1865(1):230−242. DOI:10.1016/j.bbadis.2018.08.005.; De Genst E., Foo K.S., Xiao Y., Rohner E., de Vries E., Sohlmér J. et al. Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure. Nat. Commun. 2022;13(1):3018. DOI:10.1038/s41467-022-29703-9.; Maruyama K., Imanaka-Yoshida K. The Pathogenesis of Cardiac Fibrosis: A Review of Recent Progress. Int. J. Mol. Sci. 2022;23(5):2617. DOI:10.3390/ijms23052617.; Budde H., Hassoun R., Mügge A., Kovács Á., Hamdani N. Current understanding of molecular pathophysiology of heart failure with preserved ejection fraction. Front. Physiol. 2022 July7;13: 928232. DOI:10.3389/fphys.2022.928232.; Zile M.R., Baicu C.F., Gaasch W.H. Diastolic heart failure – abnormalities in active relaxation and passive stiffness of the left ventricle. N. Engl. J. Med. 2004;350(19):1953−1959. DOI:10.1056/NEJMoa032566/; Калюжин В.В., Тепляков А.Т., Беспалова И.Д., Калюжина Е.В., Черногорюк Г.Э., Терентьева Н.Н. и др. Диастолическая сердечная недостаточность: границы применения термина. Бюллетень сибирской медицины. 2023;22(1):113– 120. DOI:10.20538/1682-0363-2023-1-113-120.; Беленков Ю.Н., Агеев Ф.Т., Мареев В.Ю. Знакомьтесь: диастолическая сердечная недостаточность. Журнал сердечная недостаточность. 2000;1(2):40–44.; Zile M.R. Heart failure with preserved ejection fraction: is this diastolic heart failure? J. Am. Coll. Cardiol. 2003;41(9):1519−1522. DOI:10.1016/s0735-1097(03)00186-4.; Калюжин В.В., Тепляков А.Т., Черногорюк Г.Э., Калюжина Е.В., Беспалова И.Д., Терентьева Н.Н. и др. Хроническая сердечная недостаточность: синдром или заболевание? Бюллетень сибирской медицины. 2020;19(1):134–139. DOI:10.20538/1682-0363-2020-1-134–139.; Mashali M.A., Saad N.S., Canan B.D., Elnakish M.T., Milani-Nejad N., Chung J.H. et al. Impact of etiology on force and kinetics of left ventricular end-stage failing human myocardium. J. Mol. Cell. Cardiol. 2021;156:7−19. DOI:10.1016/j.yjmcc.2021.03.007.; Triposkiadis F., Xanthopoulos A., Parissis J., Butler J., Farmakis D. Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. Heart Fail. Rev. 2022;27(1):337−344. DOI:10.1007/s10741-020-09987-z.; Fayol A., Wack M., Livrozet M., Carves J.B., Domengé O., Vermersch E. et al. Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. ESC Heart Fail. 2022;9(1):519−530. DOI:10.1002/ehf2.13717.; Калюжин В.В., Тепляков А.Т., Беспалова И.Д., Калюжина Е.В., Терентьева Н.Н., Гракова Е.В. и др. Перспективные направления лечения хронической сердечной недостаточности: совершенствование старых или разработка новых? Бюллетень сибирской медицины. 2022;21(3):181−197. DOI:10.20538/1682-0363-2022-3-181-197.; Капелько В.И. Почему расслабление миокарда всегда замедляется при патологии сердца? Кардиология. 2019;59(12):44−51. DOI:10.18087/cardio.2019.12.n801.; Калюжин В.В., Тепляков А.Т., Соловцов М.А. Роль систолической и диастолической дисфункции ЛЖ в клинической манифестации хронической сердечной недостаточности у больных, перенесших инфаркт миокарда. Терапевтический архив. 2002;74(12):15−18.; Капелько В.И. Диастолическая дисфункция. Кардиология. 2011;51(1):79−90.; Bronzwaer J.G., Paulus W.J. Matrix, cytoskeleton, or myofilaments: which one to blame for diastolic left ventricular dysfunction? Prog. Cardiovasc. Dis. 2005;47(4):276−284. DOI:10.1016/j.pcad.2005.02.003.; Münch J., Abdelilah-Seyfried S. Sensing and responding of cardiomyocytes to changes of tissue stiffness in the diseased heart. Front. Cell Dev. Biol. 2021Feb.26;9:642840. DOI:10.3389/fcell.2021.642840.; Капелько В.И. Роль саркомерного белка титина в насосной функции сердца. Успехи физиологических наук. 2022;53(2):39−53. DOI:10.31857/S0301179822020059.; Wadmore K., Azad A.J., Gehmlich K. The role of Z-disc proteins in myopathy and cardiomyopathy. Int. J. Mol. Sci. 2021March17;22(6):3058. DOI:10.3390/ijms22063058.; Van Wijk S.W., Su W., Wijdeveld L.F.J.M., Ramos K.S., Brundel B.J.J.M. Cytoskeletal protein variants driving atrial fibrillation: potential mechanisms of action. Cells. 2022;11(3):416. DOI:10.3390/cells11030416.; Wang Z., Grange M., Pospich S., Wagner T., Kho A.L., Gautel M. et al. Structures from intact myofibrils reveal mechanism of thin filament regulation through nebulin. Science. 2022Feb.18;375(6582):eabn1934. DOI:10.1126/science.abn1934.; Granzier H.L., Irving T.C. Passive tension in cardiac muscle: contribution of collagen, titin, microtubules, and intermediate filaments. Biophys. J. 1995;68(3):1027−1044. DOI:10.1016/S0006-3495(95)80278-X.; Fukuda N., Granzier H., Ishiwata S., Morimoto S. Editorial: recent advances on myocardium physiology. Front. Physiol. 2021May26;12:697852. DOI:10.3389/fphys.2021.697852.; Herzog W. What can we learn from single sarcomere and myofibril preparations? Front. Physiol. 2022Apr.27;13:837611. DOI:10.3389/fphys.2022.837611.; Labeit S., Kolmerer B., Linke W.A. The giant protein titin. Emerging roles in physiology and pathophysiology. Circ. Res. 1997;80(2):290−294. DOI:10.1161/01.res.80.2.290.; Azad A., Poloni G., Sontayananon N., Jiang H., Gehmlich K. The giant titin: how to evaluate its role in cardiomyopathies. J. Muscle Res. Cell Motil. 2019;40(2):159−167. DOI:10.1007/s10974-019-09518-w.; Helmes M., Trombitás K., Granzier H. Titin develops restoring force in rat cardiac myocytes. Circ. Res. 1996;79(3):619−626. DOI:10.1161/01.res.79.3.619.; Linke W.A. Titin gene and protein functions in passive and active muscle. Annu. Rev. Physiol. 2018Feb.10 80:389−411. DOI:10.1146/annurev-physiol-021317-121234.; Овчинников А.Г., Потехина А.В., Ожерельева М.В., Агеев Ф.Т. Дисфункция левого желудочка при гипертоническом сердце: современный взгляд на патогенез и лечение. Кардиология. 2017;57(S2):367–382. DOI:10.18087/cardio.2393.; Najafi A., van de Locht M., Schuldt M., Schönleitner P., van Willigenburg M., Bollen I. et al. End-diastolic force pre-activates cardiomyocytes and determines contractile force: role of titin and calcium. J. Physiol. 2019;597(17):4521−4531. DOI:10.1113/JP277985.; Koser F., Loescher C., Linke W.A. Posttranslational modifications of titin from cardiac muscle: how, where, and what for? FEBS J. 2019;286(12):2240−2260. DOI:10.1111/febs.14854.; Trombitás K., Wu Y., Labeit D., Labeit S., Granzier H. Cardiac titin isoforms are coexpressed in the half-sarcomere and extend independently. Am. J. Physiol. Heart Circ. Physiol. 2001;281(4):H1793−H1799. DOI:10.1152/ajpheart.2001.281.4.H1793.; Van Heerebeek L., Borbély A., Niessen H.W., Bronzwaer J.G., van der Velden J., Stienen G.J. et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113(16):1966−1973. DOI:10.1161/CIRCULATIONAHA.105.587519.; Katz A.M., Zile M.R. New molecular mechanism in diastolic heart failure. Circulation. 2006;113(16):1922−1925. DOI:10.1161/CIRCULATIONAHA.106.620765.; Калюжин В.В., Тепляков А.Т., Соловцов М.А., Калюжина Е.В., Беспалова И.Д., Терентьева Н.Н. Ремоделирование левого желудочка: один или несколько сценариев? Бюллетень сибирской медицины. 2016;15(4):120−139. DOI:10.20538/1682-0363-2016-4-120-139.; Lewis G.A., Schelbert E.B., Williams S.G., Cunnington C., Ahmed F., McDonagh T.A. et al. Biological phenotypes of heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 2017;70(17):2186−2200. DOI:10.1016/j.jacc.2017.09.006.; Neagoe C., Kulke M., del Monte F., Gwathmey J.K., de Tombe P.P., Hajjar R.J. et al. Titin isoform switch in ischemic human heart disease. Circulation. 2002;106(11):1333−1341. DOI:10.1161/01.cir.0000029803.93022.93.; Wu Y., Bell S.P., Trombitas K., Witt C.C., Labeit S., LeWinter M.M. et al. Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. Circulation. 2002;106(11):1384−1389. DOI:10.1161/01.cir.0000029804.61510.02.; Lahmers S., Wu Y., Call D.R., Labeit S., Granzier H. Developmental control of titin isoform expression and passive stiffness in fetal and neonatal myocardium. Circ. Res. 2004;94(4):505−513. DOI:10.1161/01.RES.0000115522.52554.86.; Weeland C.J., van den Hoogenhof M.M., Beqqali A., Creemers E.E. Insights into alternative splicing of sarcomeric genes in the heart. J. Mol. Cell. Cardiol. 2015Apr.;81:107−113. DOI:10.1016/j.yjmcc.2015.02.008.; Eldemire R., Tharp C.A., Taylor M.R.G., Sbaizero O., Mestroni L. The sarcomeric spring protein titin: biophysical properties, molecular mechanisms, and genetic mutations associated with heart failure and cardiomyopathy. Curr. Cardiol. Rep. 2021;23(9):121. DOI:10.1007/s11886-021-01550-y.; Kötter S., Krüger M. Protein quality control at the sarcomere: titin protection and turnover and implications for disease development. Front. Physiol. 2022Juny30;13:914296. DOI:10.3389/fphys.2022.914296.; Krüger M., Linke W.A. Titin-based mechanical signalling in normal and failing myocardium. J. Mol. Cell. Cardiol. 2009;46(4):490−498. DOI:10.1016/j.yjmcc.2009.01.004.; Anderson B.R., Granzier H.L. Titin-based tension in the cardiac sarcomere: molecular origin and physiological adaptations. Prog. Biophys. Mol. Biol. 2012;110(2-3):204−217. DOI:10.1016/j.pbiomolbio.2012.08.003.; Radke M.H., Polack C., Methawasin M., Fink C., Granzier H.L., Gotthardt M. Deleting full length titin versus the titin m-band region leads to differential mechanosignaling and cardiac phenotypes. Circulation. 2019;139(15):1813−1827. DOI:10.1161/CIRCULATIONAHA.118.037588.; Zhu C., Yin Z., Ren J., McCormick R.J., Ford S.P., Guo W. RBM20 is an essential factor for thyroid hormone-regulated titin isoform transition. J. Mol. Cell. Biol. 2015;7(1):88−90. DOI:10.1093/jmcb/mjv002.; Борисов А.А., Гвоздева А.Д., Агеев Ф.Т. Сердечная недостаточность с сохраненной фракцией выброса у пациентов с сахарным диабетом 2 типа: от патогенеза к лечению. Медицинский вестник Юга России. 2021;12(2):6−15. DOI:10.21886/2219-8075-2021-12-2-6-15.; Krüger M., Babicz K., von Frieling-Salewsky M., Linke W.A. Insulin signaling regulates cardiac titin properties in heart development and diabetic cardiomyopathy. J. Mol. Cell. Cardiol. 2010May;48(5): 910−916. DOI:10.1016/j.yjmcc.2010.02.012.; Zhu C., Yin Z., Tan B., Guo W. Insulin regulates titin pre-mRNA splicing through the PI3K-Akt-mTOR kinase axis in a RBM20-dependent manner. Biochim. Biophys. Acta Mol. Basis Dis. 2017;1863(9):2363−2371. DOI:10.1016/j.bbadis.2017.06.023.; Bernal J., Pitta S.R., Thatai D. Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. Am. J. Cardiovasc. Drugs. 2006;6(6):373−381. DOI:10.2165/00129784-200606060-00004.; Останко В.Л., Калачева Т.П., Калюжина Е.В., Лившиц И.К., Шаловай А.А., Черногорюк Г.Э., Беспалова И.Д. и др. Биологические маркеры в стратификации риска развития и прогрессирования сердечно-сосудистой патологии: настоящее и будущее. Бюллетень сибирской медицины. 2018;17(4):264−280. DOI:10.20538/1682-0363-2018-4-264-280.; Cai H., Zhu C., Chen Z., Maimaiti R., Sun M., McCormick R.J. et al. Angiotensin II Influences Pre-mRNA splicing regulation by enhancing RBM20 transcription through activation of the MAPK/ELK1 signaling pathway. Int. J. Mol. Sci. 2019;20(20):5059. DOI:10.3390/ijms20205059.; Rocha R., Almeida-Coelho J., Leite-Moreira A.M., Neves J.S., Hamdani N., Falcão-Pires I. et al. Titin phosphorylation by protein kinase G as a novel mechanism of diastolic adaptation to acute load: PS146. Porto Biomed. J. 2017;2(5):185. DOI:10.1016/j.pbj.2017.07.024.; Michel K., Herwig M., Werner F., Špiranec Spes K., Abeßer M., Schuh K. et al. C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness. JCI Insight. 2020Nov.19;5(22):e139910. DOI:10.1172/jci.insight.139910.; Herwig M., Kolijn D., Lódi M., Hölper S., Kovács Á., Papp Z. et al. Modulation of titin-based stiffness in hypertrophic cardiomyopathy via protein kinase D. Front. Physiol. 2020Apr.15;11:240. DOI:10.3389/fphys.2020.00240.; Murphy S., Frishman W.H. Protein kinase C in cardiac disease and as a potential therapeutic target. Cardiol. Rev. 2005;13(1):3−12. DOI:10.1097/01.crd.0000124914.59755.8d.; Hidalgo C., Hudson B., Bogomolovas J., Zhu Y., Anderson B., Greaser M., Labeit S. et al. PKC phosphorylation of titin’s PEVK element: a novel and conserved pathway for modulating myocardial stiffness. Circ. Res. 2009;105(7):631–638. DOI:10.1161/CIRCRESAHA.109.198465.; Soetkamp D., Gallet R., Parker S.J., Holewinski R., Venkatraman V., Peck K. et al. Myofilament phosphorylation in stem cell treated diastolic heart failure. Circ. Res. 2021;129(12):1125−1140. DOI:10.1161/CIRCRESAHA.119.316311.; Krysiak J., Unger A., Beckendorf L., Hamdani N., von Frieling-Salewsky M., Redfield M.M. et al. Protein phosphatase 5 regulates titin phosphorylation and function at a sarcomere-associated mechanosensor complex in cardiomyocytes. Nat. Commun. 2018Jan.17;9(1):262. DOI:10.1038/s41467-017-02483-3.; Manilall A., Mokotedi L., Gunter S., Le Roux R., Fourie S., Flanagan C.A. et al. Increased protein phosphatase 5 expression in inflammation-induced left ventricular dysfunction in rats. BMC Cardiovasc. Disord. 2022Dec.9;22(1):539. DOI:10.1186/s12872-022-02977-z.; Gömöri K., Herwig M., Budde H., Hassoun R., Mostafi N., Zhazykbayeva S. et al. Ca2+/calmodulin-dependent protein kinase II and protein kinase G oxidation contributes to impaired sarcomeric proteins in hypertrophy model. ESC Heart Fail. 2022;9(4):2585−2600. DOI:10.1002/ehf2.13973.; Bevere M., Morabito C., Mariggiò M.A., Guarnieri S. The oxidative balance orchestrates the main keystones of the functional activity of cardiomyocytes. Oxid. Med. Cell. Longev. 2022Jan.10;2022:7714542. DOI:10.1155/2022/7714542.; Nagueh S.F. Heart failure with preserved ejection fraction: insights into diagnosis and pathophysiology. Cardiovasc. Res. 2021;117(4): 999−1014. DOI:10.1093/cvr/cvaa228.; Røe Å.T., Ruud M., Espe E.K., Manfra O., Longobardi S., Aronsen J.M. et al. Regional diastolic dysfunction in post-infarction heart failure: role of local mechanical load and SERCA expression. Cardiovasc. Res. 2019; 15(4):752−764. DOI:10.1093/cvr/cvy257.; Eisner D.A., Caldwell J.L., Trafford A.W., Hutchings D.C. the control of diastolic calcium in the heart: basic mechanisms and functional implications. Circ. Res. 2020;126(3):395−412. DOI:10.1161/CIRCRESAHA.119.315891.; Granzier H., Labeit S. Cardiac titin: an adjustable multi-functional spring. J. Physiol. 2002;541(Pt2):335−342. DOI:10.1113/jphysiol.2001.014381.; Liu C., Lai Y., Pei J., Huang H., Zhan J., Ying S. et al. Clinical and genetic analysis of KATP variants with heart failure risk in patients with decreased serum ApoA-I levels. J. Clin. Endocrinol. Metab. 2021;106(8):2264−2278. DOI:10.1210/clinem/dgab336.; Liu C., Lai Y., Guan T., Zhan J., Pei J., Wu D. et al. Associations of ATP-sensitive potassium channel’s gene polymorphisms with type 2 diabetes and related cardiovascular phenotypes. Front. Cardiovasc. Med. 2022March23;9:816847. DOI:10.3389/fcvm.2022.816847.; https://bulletin.ssmu.ru/jour/article/view/5315

الاتاحة: https://bulletin.ssmu.ru/jour/article/view/5315
https://doi.org/10.20538/1682-0363-2023-3-98-109

المؤلفون: E. V. Grakova, K. V. Kopeva, S. N. Shilov, E. T. Bobyleva, E. N. Berezikova, V. V. Kalyuzhin, A. T. Teplyakov, Е. В. Гракова, К. В. Копьева, С. Н. Шилов, Е. Т. Бобылева, Е. Н. Березикова, В. В. Калюжин, А. Т. Тепляков

المساهمون: The study was carried out within the basic research “Study of the mechanisms of structural and functional myocardial remodeling in different phenotypes in heart failure of ischemic and non-ischemic etiology” No.122020300045-5, Фундаментальное научное исследование «Изучение механизмов структурного и функционального ремоделирования миокарда при разных фенотипах хронической сердечной недостаточности ишемической и неишемической этиологии» (№ 122020300045-5)

المصدر: Bulletin of Siberian Medicine; Том 22, № 3 (2023); 25-35 ; Бюллетень сибирской медицины; Том 22, № 3 (2023); 25-35 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2023-22-3

مصطلحات موضوعية: прогноз, anthracyclines, humoral markers, prognosis, антрациклины, гуморальные маркеры

وصف الملف: application/pdf

Relation: https://bulletin.ssmu.ru/jour/article/view/5302/3434; https://bulletin.ssmu.ru/jour/article/view/5302/3453; Adhikari A., Asdaq S.M.B., Al Hawaj M.A., Chakraborty M., Thapa G., Bhuyan N.R. et al. Anticancer drug-induced cardiotoxicity: insightsand pharmacogenetics. Pharmaceuticals (Basel). 2021;14(10):970. DOI:10.3390/ph14100970.; Saleh Y., Abdelkarim O., Herzallah K., Abela G.S. Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment. Heart Fail Rev. 2021;26(5):1159–1173. DOI:10.1007/s10741-020-09968-2.; Curigliano G., Cardinale D., Dent S., Criscitiello C., Aseyev O., Lenihan D. et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J. Clin. 2016;66(4):309–325. DOI:10.3322/caac.21341.; Zamorano J.L., Lancellotti P., Rodriguez Munoz D., Aboyans V., Asteggiano R., Galderisi M. et al. ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology. Eur. J. Heart Fail. 2017;19(1):9–42. DOI:10.1002/ejhf.654.; Lakhani H.V., Pillai S.S., Zehra M., Dao B., Tirona M.T., Thompson E. et al. Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer. Sci. Rep. 2021;11(1):7954. DOI:10.1038/s41598-021-87209-8.; Mitry M.A., Edwards J.G. Doxorubicin induced heart failure: phenotype and molecular mechanisms. Int. J. Cardiol. Heart Vasc. 2016;10:17–24. DOI:10.1016/j.ijcha.2015.11.004.; Fabiani I., Aimo A., Grigoratos C., Castiglione V., Gentile F., Saccaro L.F. et al. Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. Heart Fail Rev. 2021;26(4):881–890. DOI:10.1007/s10741-020-10063-9.; Bansal N., Adams M.J., Ganatra S., Colan S.D., Aggarwal S., Steiner R. et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology. 2019;5:1– 22. DOI:10.1186/s40959-019-0054-5.; Songbo M., Lang H., Xinyong C., Bin X., Ping Z., Liang S. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol. Lett. 2019;307:41–48. DOI:10.1016/j.toxlet.2019.02.013.; Aminkeng F., Ross C.J., Rassekh S.R., Hwang S., Rieder M.J., Bhavsar A.P. et al. CPNDS Clinical Practice Recommendations Group. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br. J. Clin. Pharmacol. 2016;82(3):683–695. DOI:10.1111/bcp.13008.; Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J. et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J. 20221;43(41):4229–4361. DOI:10.1093/eurheartj/ehac244.; Capranico G., Tinelli S., Austin C.A., Fisher M.L., Zunino F. Different patterns of gene expression of topoisomerase 2 isoforms in differentiated tissues during murine development. Biochim. Biophys. Acta. 1992;1132(1):43–48. DOI:10.1016/0167-4781(92)90050-A.; Grakova E.V., Shilov S.N., Kopeva K.V., Berezikova E.N., Popova A.A., Neupokoeva M.N. et al. Extracellular matrix remodeling in anthracycline-induced cardiotoxicity: What place on the pedestal? Int. J. Cardiol. 2022;350:55–61. DOI:10.1016/j.ijcard.2022.01.013.; Adamcová M., Potáčová A., Popelová O. et al. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiol. Res. 2010;59(5):831–836. DOI:10.33549/physiolres.931797.; Saleh Y., Abdelkarim O., Herzallah K. Abela G.S. Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment. Heart Fail Rev. 2021;26(5):1159–1173. DOI:10.1007/s10741-020-09968-2.; Leerink J.M., van de Ruit M., Feijen E.A.M. et al. Extracellular matrix remodeling in animal models of anthracycline-induced cardiomyopathy: a meta-analysis. J. Mol. Med. (Berlin). 2021;99(9):1195–1207. DOI:10.1007/s00109-021-02098-8.; Octavia Y., Tocchetti C.G., Gabrielson K.L., Janssens S., Crijns H.J., Moens A.L. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell Cardiol. 2012;52(6):1213–1225. DOI:10.1016/j.yjmcc.2012.03.006.; Vanhoutte D., Heymans S. TIMPs and cardiac remodeling: ‘embracing the MMP-independent-side of the family’. J. Mol. Cell Cardiol. 2010;48(3):445–453. DOI:10.1016/j.yjmcc.2009.09.013.; Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu. Rev. Pharmacol. Toxicol. 2007;47:211–242. DOI:10.1146/annurev.pharmtox.47.120505.105230.; Chan B.Y.H., Roczkowsky A., Cho W.J., Poirier M., Sergi C., Keschrumrus V. et al. MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodeling. Cardiovasc. Res. 2021;117(1):188–200. DOI:10.1093/cvr/cvaa017.; Fanjul-Fernández M., Folgueras A.R., Cabrera S., LópezOtín C. Matrix metalloproteinases: Evolution, gene regulation and functional analysis in mouse models. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research. 2010;1803(1):3–19. DOI:10.1016/j.bbamcr.2009.07.004.; Alfonso-Jaume M.A., Bergman M.R., Mahimkar R., Cheng S., Jin Z.Q., Karliner J.S. et al. Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am. J. Physiol. Heart Circ. Physiol. 2006;291(4):H1838–H1846. DOI:10.1152/ajpheart.00026.2006.; Chan B.Y.H., Roczkowsky A., Moser N., Poirier M., Hughes B.G., Ilarraza R. et al. Doxorubicin induces de novo expression of N-terminal-truncated matrix metalloproteinase-2 in cardiac myocytes. Can. J. Physiol. Pharmacol. 2018;96(12):1238–1245. DOI:10.1139/cjpp-2018-0275.; Spinale F.G., Janicki J.S., Zile M.R. Membrane-associated matrix proteolysis and heart failure. Circ. Res. 2013;112(1):195– 208. DOI:10.1161/CIRCRESAHA.112.266882.; Ivanová M., Dovinová I., Okruhlicová L., Tribulová N., Simončíková P., Barteková M. et al. Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats. Acta Pharmacol. Sin. 2012;33(4):459–469. DOI:10.1038/aps.2011.194.; Toro-Salazar O.H., Lee J.H., Zellars K.N., Perreault P.E., Mason K.C., Wang Z. et al. Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines. Cardiooncology. 2018;4:4. DOI:10.1186/s40959-018-0030-5.; Wewer U.M., Ibaraki K., Schjørring P., Durkin M.E., Young M.F., Albrechtsen R. A potential role for tetranectin in mineralization during osteogenesis. J. Cell Biol. 1994;127(6Pt1):1767–1775. DOI:10.1083/jcb.127.6.1767.; Nielsen H., Clemmensen I., Kharazmi A. Tetranectin: a novel secretory protein from human monocytes. Scand. J. Immunol. 1993;37(1):39–42. DOI:10.1111/j.1365-3083.1993.tb01662.x.; Christensen L., Clemmensen I. Tetranectin immunoreactivity in normal human tissues. An immunohistochemical study of exocrine epithelia and mesenchyme. Histochemistry. 1989;92(1):29–35. DOI:10.1007/BF00495012.; Ho J.E., Lyass A., Courchesne P., Chen G., Liu C., Yin X. et al. Protein biomarkers of cardiovascular disease and mortality in the community. J. Am. Heart Assoc. 2018;13;7(14):e008108. DOI:10.1161/JAHA.117.008108.; Mogues T., Etzerodt M., Hall C., Engelich G., Graversen J.H., Hartshorn K.L. Tetranectin binds to the kringle 1-4 form of angiostatin and modifies its functional activity. J. Biomed. Biotechnol. 2004;2004(2):73–78. DOI:10.1155/S1110724304307096.; McDonald K., Glezeva N., Collier P. Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis. Sci. Rep. 2020;10(1):7507. DOI:10.1038/s41598-020-64558-4.; Iba K., Hatakeyama N., Kojima T., Murata M., Matsumura T., Wewer U.M. et al. Impaired cutaneous wound healing in mice lacking tetranectin. Wound Repair Regen. 2009;17(1):108– 112. DOI:10.1111/j.1524-475X.2008.00447.x.; Chen Y., Han H., Yan X., Ding F., Su X., Wang H. et al. Tetranectin as a potential biomarker for stable coronary artery disease. Sci. Rep. 2015;5:17632. DOI:10.1038/srep17632.; Копьева К.В., Тепляков А.Т., Гракова Е.В., Солдатенко М.В., Огуркова О.Н., Ахмедов Ш.Д. Роль нового биомаркераST2 в оценке ремоделирования миокарда у больных хронической сердечной недостаточностью ишемического генеза с сохраненной фракцией выброса левого желудочка. Кардиология. 2018;58(10S):33–43. DOI:10.18087/cardio.2498.; Garbern J.C., Williams J., Kristl A.C., Malick A., Rachmin I., Gaeta B. et al. Dysregulation of IL-33/ST2 signaling and myocardial periarteriolar fibrosis. J. Mol. Cell Cardiol. 2019;128:179–186. DOI:10.1016/j.yjmcc.2019.01.018.; Останко В.Л., Калачева Т.П., Калюжина Е.В., Лившиц И.К., Шаловай А.А., Черногорюк Г.Э. и др. Биологические маркеры в стратификации риска развития и прогрессирования сердечно-сосудистой патологии: настоящее и будущее. Бюллетень сибирской медицины. 2018;17(4):264−280. DOI:10.20538/1682-0363-2018-4-264-280.; https://bulletin.ssmu.ru/jour/article/view/5302

الاتاحة: https://bulletin.ssmu.ru/jour/article/view/5302
https://doi.org/10.20538/1682-0363-2023-3-25-35

المؤلفون: K. V. Kopeva, A. N. Maltseva, E. V. Grakova, A. V. Mochula, M. V. Soldatenko, V. V. Kalyuzhin, K. V. Zavadovsky, К. В. Копьева, А. Н. Мальцева, Е. B. Гракова, А. В. Мочула, М. В. Солдатенко, В. В. Калюжин, К. В. Завадовский

المساهمون: The study was supported by the grant awarded by the President of the Russian Federation No. MK-4257.2022.3., Исследование выполнено при поддержке гранта Президента Российской Федерации № MK-4257.2022.3.

المصدر: Bulletin of Siberian Medicine; Том 22, № 1 (2023); 41-50 ; Бюллетень сибирской медицины; Том 22, № 1 (2023); 41-50 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2023-22-1

مصطلحات موضوعية: натрийуретический пептид, preserved ejection fraction, myocardial flow reserve, prognosis, natriuretic peptide, сохраненная фракция выброса, резерв миокардиального кровотока, прогноз

وصف الملف: application/pdf

Relation: https://bulletin.ssmu.ru/jour/article/view/5130/3347; Roger V.L. Epidemiology of heart failure. a contemporary perspective. Circulation Research. 2021;128(10):1421–1434. DOI:10.1161/CIRCRESAHA.121.318172.; Clark K.A.A., Velazquez E.J. Heart failure with preserved ejection fraction: Time for a reset. JAMA. 2020;324(15):1506– 1508. DOI:10.1001/jama.2020.15566.; Chan D.Z.L., Kerr A.J., Rob N. Doughty. Temporal trends in the burden of heart failure. Intern. Med. J. 2021;51(8):1212– 1218. DOI:10.1111/imj.15253.; Mamas M.A., Sperrin M., Watson M.C., Coutts A., Wilde K., Burton C. et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur. J. Heart Fail. 2017;19(9):1095–1004. DOI:10.1002/ejhf.822.; Lesyuk W., Kriza C., Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004–2016. BMC Cardiovasc. Disord. 2018;18(1):74. DOI:10.1186/s12872-018-0815-3.; Wintrich J., Kindermann I., Ukena C., Selejan S., Werner C., Maack C. et al. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clin. Res. Cardiol. 2021;109(9):1079–1098. DOI:10.1007/s00392-02001633-w.; McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M. et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2021;42(36):3599–3726. DOI:10.1093/eurheartj/ehab368.; Tona F., Montisci R., Iop L., Civieri G. Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction. Rev. Cardiovasc. Med. 2021;22(1):97–104. DOI:10.31083/j.rcm.2021.01.277.; Mileva N., Nagumo S., Mizukami T., Sonck J., Berry C., Gallinoro E. et al. Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2022;11(7):e023207. DOI:10.1161/JAHA.121.023207.; Murthy V.L., Naya M., Taqueti V.R., Foster C.R., Gaber M., Hainer J. et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014;129(24):2518– 2527. DOI:10.1161/CIRCULATIONAHA.113.008507.; Rush C.J., Berry C., Oldroyd K.G. et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6(10):1130–1143. DOI:10.1001/jamacardio.2021.1825.; Shah S.J., Lam C.S.P., Svedlund S., Saraste A., Hage C., Tan R.S. et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. European Heart Journal. 2018;39(37):3439–3450. DOI:10.1093/eurheartj/ehy531.; Taqueti V.R., Di Carli M.F. Clinical significance of noninvasive coronary flow reserve assessment in patients with ischemic heart disease. Curr. Opin. Cardiol. 2016;31(6):662–669. DOI:10.1097/HCO.0000000000000339.; Ong P., Safdar B., Seitz A., Hubert A., Beltrame J.F., Prescott E. Diagnosis of coronary microvascular dysfunction in the clinic. Cardiovasc. Res. 2020;116(4):841–855. DOI:10.1093/cvr/cvz339.; Driessen R.S., Raijmakers P.G., Stuijfzand W.J., Knaapen P. Myocardial perfusion imaging with PET. Int. J. Cardiovasc. Imaging. 2017;33(7):1021–1031. DOI:10.1007/s10554-0171084-4.; Zavadovsky K.V., Mochula A.V., Boshchenko A.A., Vrublevsky A.V., Baev A.E., Krylov A.L. et al. Absolute myocardial blood flows derived by dynamic CZT scan vs invasive fractional flow reserve: correlation and accuracy. J. Nucl. Cardiol. 2021;28(1):249–259. DOI:10.1007/s12350-019-01678-z.; Zavadovsky K.V., Mochula A.V., Maltseva A.N., Boshchenko A.A., Baev A.E., Andreev S.L. et al. The diagnostic value of SPECT CZT quantitative myocardial blood flow in highrisk patients. J. Nucl. Cardiol. 2022June;29(3):1051–1063. DOI:10.1007/s12350-020-02395-8; Austen W.G., Edwards J.E., Frye R.L., Gensini G.G., Gott V.L., Griffith L.S. et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery. American Heart Association. Circulation. 1975;51(4):5–40. DOI:10.1161/01.cir.51.4.5; Nagueh S.F., Smiseth O.A., Appleton C.P. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2016;17(12):1321–1360. DOI:10.1093/ehjci/jew082.; Yang J.H., Obokata M., Reddy Y.N., Redfield M.M., Lerman A., Borlaug B.A. Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Eur. J. Heart Fail. 2020;22(3):432–441. DOI:10.1002/ejhf.1671.; Obokata M., Reddy Y.N., Melenovsky V., Kane G.C., Olson T.P., Jarolim P. et al. Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction. J. Am. Coll. Cardiol. 2018;72(1):29–40. DOI:10.1016/j.jacc.2018.04.039.; Ahmad A., Corban M.T., Toya T., Verbrugge F.H., Sara J.D., Lerman L.O. et al. Coronary microvascular dysfunction is as sociated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction. Eur. J. Heart Fail. 2021;23(5):765–772. DOI:10.1002/ejhf.2010.; Sinha A., Rahman H., Webb A., Shah A.M., Perera D. Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction. European Heart Journal. 2021;42(43):4431–4441. DOI:10.1093/eurheartj/ehab653.; Mohammed S.F., Hussain S., Mirzoyev S.A., Edwards W.D., Maleszewski J.J., Redfield M.M. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131(6):550–559. DOI:10.1161/CIRCULATIONAHA.114.009625.; Bairey Merz C.N., Pepine C.J., Shimokawa H., Berry C. Treatment of coronary microvascular dysfunction. Cardiovasc. Research. 2022;116(4):856–870. DOI:10.1093/cvr/cvaa006.; Zhou W., Lee J.C.Y., Leung S.T., Lai A., Lee T.F., Chiang J.B. et al. , Long-term prognosis of patients with coronary microvascular disease using stress perfusion cardiac magnetic resonance. JACC Cardiovasc. Imaging. 2021;14(3):602–611. DOI:10.1016/j.jcmg.2020.09.034.; Liga R., Neglia D., Kusch A., Favilli B., Giorgetti A., Gimelli A. Prognostic role of dynamic CZT imaging in CAD patients: interaction between absolute flow and CAD burden. JACC Cardiovasc. Imaging. 2022;15(3):540–542. DOI:10.1016/j.jcmg.2021.09.030.; Boden W.E., O’Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J. et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 2007;356(15):1503–1516. DOI:10.1056/NEJMoa070829.; Maron D.J., Hochman J.S., Reynolds H.R., Bangalore S., O’Brien S.M., Boden W.E. et al. ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. N. Engl. J. Med. 2020;382(15):1395–1407. DOI:10.1056/NEJMoa1915922.; Shimokawa H., Suda A., Takahashi J., Berry C., Camici P.G., Crea F. et al. Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. Eur. Heart J. 2021;42(44):4592–4600. DOI:10.1093/eurheartj/ehab282.; Schroder J., Michelsen M.M., Mygind N.D., Suhrs H.E., Bove K.B., Bechsgaard D.F. et al. Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study. Eur. Heart J. 2021;42(3):228–239. DOI:10.1093/ eurheartj/ehaa944.; Kato S., Fukui K., Kodama S., Azuma M., Nakayama N., Iwasawa T. et al. Cardiovascular magnetic resonance assessment of coronary flow reserve improves risk stratification in heart failure with preserved ejection fraction. J. Cardiovasc. Magn. Reson. 2021;23(1):112. DOI:10.1186/s12968-02100807-3.; Lam J.H., Quah J.X., Davies T., Boos C.J., Nel K., Anstey C.M. et al. Relationship between coronary microvascular dysfunction and left ventricular diastolic function in patients with chest pain and unobstructed coronary arteries. Echocardiography. 2020;37(8):1199–1204. DOI:10.1111/echo.14794.; Snoer M., Monk-Hansen T., Olsen R.H., Pedersen L.R., Nielsen O.W., Rasmusen H. et al. Coronary flow reserve as a link between diastolic and systolic function and exercise capacity in heart failure. Eur. Heart J. Cardiovasc. Imaging. 2013;14(7):677–683. DOI:10.1093/ehjci/jes269.; Crea F., Bairey Merz C.N., Beltrame J.F., Kaski J.C., Ogawa H., Ong P., Sechtem U., Shimokawa H., Camici P.G. The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. Eur. Heart J. 2017;38(7):473–477. DOI:10.1093/eurheartj/ehw461.; Filali Y., Kesäniemi A., Ukkola O. Soluble ST2, a biomarker of fibrosis, is associated with multiple risk factors, chronic diseases and total mortality in the OPERA study. Scand. J. Clin. Lab. Invest. 2021;81(4):324–331. DOI:10.1080/00365513.2021.1904518.; https://bulletin.ssmu.ru/jour/article/view/5130

الاتاحة: https://bulletin.ssmu.ru/jour/article/view/5130
https://doi.org/10.20538/1682-0363-2023-1-41-50

المؤلفون: E. V. Grakova, K. V. Kopeva, S. N. Shilov, E. N. Berezikova, A. A. Popova, M. N. Neupokoeva, E. T. Ratushnyak, V. V. Kalyuzhin, A. T. Teplyakov, Е. В. Гракова, К. В. Копьева, С. Н. Шилов, Е. Н. Березикова, А. А. Попова, М. Н. Неупокоева, Е. Т. Ратушняк, В. В. Калюжин, А. Т. Тепляков

المساهمون: Basic research “Study of the mechanisms of structural and functional myocardial remodeling in different phenotypes in heart failure of ischemic and non-ischemic etiology” No. 122020300045-5, Фундаментальное научное исследование «Изучение механизмов структурного и функционального ремоделирования миокарда при разных фенотипах хронической сердечной недостаточности ишемической и неишемической этиологии» № 122020300045-5

المصدر: Bulletin of Siberian Medicine; Том 21, № 4 (2022); 44-53 ; Бюллетень сибирской медицины; Том 21, № 4 (2022); 44-53 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2022-21-4

مصطلحات موضوعية: ингибитор ангиотензинпревращающего фермента, heart failure, gene polymorphisms, β-blocker, angiotensin-converting enzyme inhibitor, сердечная недостаточность, полиморфизмы генов, β-адреноблокатор

وصف الملف: application/pdf

Relation: https://bulletin.ssmu.ru/jour/article/view/5020/3301; https://bulletin.ssmu.ru/jour/article/view/5020/3326; Тепляков А.Т., Шилов С.Н., Попова А.А., Гракова Е.В., Березикова Е.Н., Неупокоева М.Н. и др. Состояние сердечно-сосудистой системы у больных с антрациклиновой кардиомиопатией. Бюллетень сибирской медицины. 2017;16(3):127–136. DOI:10.20538/1682-0363-2017-3-127136.; Kheiri B., Abdalla A., Osman M., Haykal T., Chahine A., Ahmed S. et al. Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity. Am. J. Cardiol. 2018;122(11):1959–1964. DOI:10.1016/j.amjcard.2018.08.039.; McCune C., McGowan M., Johnston R., McCarthy A., Watson C., Dixon L. The prevalence of late anthracycline induced cardiotoxicity in survivors of childhood malignancy in Northern Ireland. Heart. 2019;105:A52. DOI:10.1136/heartjnl-2019ICS.64.; Volkova M., Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr. Cardiol. Rev. 2011;7(4):214–220. DOI:10.2174/157340311799960645.; Janbabai G., Nabati M., Faghihinia M., Azizi S., Borhani S., Yazdani J. Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovasc. Toxicol. 2017;17(2):130– 139. DOI:10.1007/s12012-016-9365-z.; Cardinale D., Colombo A., Lamantia G., Colombo N., Civelli M., De Giacomi G. et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 2010;19;55(3):213–220. DOI:10.1016/j.jacc.2009.03.095.; Aminkeng F., Ross C.J., Rassekh S.R., Hwang S., Rieder M.J., Bhavsar A.P. et al. CPNDS Clinical Practice Recommendations Group. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br. J. Clin. Pharmacol. 2016;82(3):683–695. DOI:10.1111/bcp.13008.; Elitok A., Oz F., Cizgici A.Y., Kilic L., Ciftci R., Sen F. et al. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. Cardiol. J. 2014;21(5):509–515. DOI:10.5603/CJ.a2013.0150.; Bansal N., Adams M.J., Ganatra S., Colan S.D., Aggarwal S., Steiner R. et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology. 2019;2;5:18. DOI:10.1186/s40959-019-0054-5.; Book W.M. Carvedilol: a nonselective β blocking agent with antioxidant properties. Congestive Heart Failure. 2002;8:173– 190. DOI:10.1111/j.1527-5299.2002.00718.x.; Nabati M., Janbabai G., Baghyari S., Esmaili K., Yazdani J. Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J. Cardiovasc. Pharmacol. 2017;69(5):279–285. DOI:10.1097/FJC.0000000000000470.; Avila M.S., Ayub-Ferreira S.M., de Barros Wanderley M.R. et al. Carvedilol for Prevention of ChemotherapyRelated Cardiotoxicity: The CECCY Trial. J. Am. Coll. Cardiol. 2018;22;71(20):2281–2290. DOI:10.1016/j.jacc.2018.02.049.; Guglin M., Krischer J., Tamura R., Fink A., Bello-Matricaria L., McCaskill-Stevens W. et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. J. Am. Coll. Cardiol. 2019;11;73(22):2859–2868. DOI:10.1016/j.jacc.2019.03.495.; Cardinale D., Colombo A., Sandri M., Lamantia G., Colombo N., Civelli M. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;5;114(23):2474–2481. DOI:10.1161/CIRCULATIONAHA.106.635144.; Silber J.H., Cnaan A., Clark B.J., Paridon S.M., Chin A.J., Rychik J. et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. 2004;1;22(5):820–828. DOI:10.1200/JCO.2004.06.022.; Bosch X., Rovira M., Sitges M., Domènech A., Ortiz-Pérez J.T., de Caralt T.M. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J. Am. Coll. Cardiol. 2013;11;61(23):2355–2362. DOI:10.1016/j.jacc.2013.02.072.; Nazarenko M.S., Markov A.V., Sleptsov A.A. et al. Comparative analysis of gene expression in vascular cells of patients with advanced atherosclerosis. Biomed. Khim. 2018;64(5):416–442. DOI:10.18097/PBMC20186405416.; Brodde O.E. Beta1and beta2-adrenoceptor polymorphisms and cardiovascular diseases. Fundam. Clin. Pharmacol. 2008;22(2):107–125. DOI:10.1111/j.1472-8206.2007.00557.x.; Baudhuin L.M., Miller W.L., Train L., Bryant S., Hartman K.A., Phelps M. et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am. J. Cardiol. 2010;1;106(3):402–408. DOI:10.1016/j.amjcard.2010.03.041.; Metra M., Covolo L., Pezzali N., Zacà V., Bugatti S., Lombardi C. et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc. Drugs Ther. 2010;24(1):49–60. DOI:10.1007/s10557-010-6220-5.; Chen L., Meyers D., Javorsky G., Burstow D. et al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet. Genomics. 2007;17(11):941–949. DOI:10.1097/FPC.0b013e3282ef7354.; Luzum J.A., Sweet K.M., Binkley P.F., Schmidlen T.J., Jarvis J.P., Christman M.F. et al. CYP2D6 genetic variation and beta-blocker maintenance dose in patients with heart failure. Pharm. Res. 2017;34(8):1615–1625. DOI:10.1007/s11095017-2104-8.; Shihmanter R., Nulman I., Goland S., Caspi A., Bar-Haim A., Harary I. et al. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure. J. Clin. Pharm. Ther. 2014;39(4):432–438. DOI:10.1111/jcpt.12154.; Katsarou M.S., Karathanasopoulou A., Andrianopoulou A., Desiniotis V., Tzinis E., Dimitrakis E. et al. Beta 1, Beta 2 and Beta 3 adrenergic receptor gene polymorphisms in a southeastern European population. Front. Genet. 2018;28;9:560. DOI:10.3389/fgene.2018.00560.; Uemura K., Nakura J., Kohara K. Miki T. Association of ACE I/D polymorphism with cardiovascular risk factors. Hum Genet. 2000; 107(3):239-42. doi:10.1007/s004390000358.; Niu T., Chen X., Xu X. Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications. Drugs. 2002;62(7):977–993. DOI:10.2165/00003495-200262070-00001.; https://bulletin.ssmu.ru/jour/article/view/5020

الاتاحة: https://bulletin.ssmu.ru/jour/article/view/5020
https://doi.org/10.20538/1682-0363-2022-4-44-53

المؤلفون: I. D. Bespalova, V. V. Kalyuzhin, B. Yu. Murashev, I. A. Osikhov, Yu. I. Koshchavtseva, A. V. Teteneva, D. S. Romanov, U. M. Strashkova, И. Д. Беспалова, В. В. Калюжин, Б. Ю. Мурашев, И. А. Осихов, Ю. И. Кощавцева, А. В. Тетенева, Д. С. Романов, У. М. Страшкова

المصدر: The Siberian Journal of Clinical and Experimental Medicine; Том 37, № 3 (2022); 114-120 ; Сибирский журнал клинической и экспериментальной медицины; Том 37, № 3 (2022); 114-120 ; 2713-265X ; 2713-2927

مصطلحات موضوعية: активные формы кислорода, visceral adipose tissue, adipose tissue inflammation, subpopulation composition of cells, reactive oxygen species, висцеральная жировая ткань, воспаление жировой ткани, субпопуляционный состав клеток

وصف الملف: application/pdf

Relation: https://cardiotomsk.elpub.ru/jour/article/view/1512/735; Ким О.Т., Драпкина О.М. Эпидемия ожирения через призму эволюционных процессов. Кардиоваскулярная терапия и профилактика. 2022;21(1):3109. DOI:10.15829/1728-8800-2022-3109.; Manna P., Jain S.K. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: Causes and therapeutic strategies. Metab. Syndr. Relat. Disord. 2015;13(10):423–444. DOI:10.1089/met.2015.0095.; Беспалова И.Д., Бычков В.А., Калюжин В.В., Рязанцева Н.В., Медянцев Ю.А., Осихов И.А. и др. Качество жизни больных гипертонической болезнью с метаболическим синдромом: взаимосвязь с маркерами системного воспаления. Бюллетень сибирской медицины. 2013;12(6):5–11. DOI:10.20538/1682-0363-2013-6-5-11.; Jankowska A., Brzeziński M., Romanowicz-Sołtyszewska A., Szlagatys Sidorkiewicz A. Metabolic syndrome in obese children-clinical prevalence and risk factors. Int. J. Environ. Res. Public Health. 2021;18(3):1060. DOI:10.3390/ijerph18031060.; Fernández-Sánchez A., Madrigal-Santillán E., Bautista M., Esquivel-Soto J., Morales-González A., Esquivel-Chirino C. et al. Infl ammation, oxidative stress, and obesity. Int. J. Mol. Sci. 2011;12(5):3117–3132. DOI:10.3390/ijms12053117.; Engin A. The pathogenesis of obesity-associated adipose tissue infl ammation. Adv. Exp. Med. Biol. 2017;960:221–245. DOI:10.1007/978-3-319-48382-5_9.; Flores-Cortez Y.A., Barragán-Bonilla M.I., Mendoza-Bello J.M., González-Calixto C., Flores-Alfaro E., Espinoza-Rojo M. Interplay of retinol binding protein 4 with obesity and associated chronic alterations (Review). Mol. Med. Res. 2022;26(1). DOI:10.3892/mmr.2022.12760.; Liu W., Zhou H., Wang H., Zhang Q., Zhang R., Willard B. et al. IL-1R-IRAKM-Slc25a1 signaling axis reprograms lipogenesis in adipocytes to promote diet-induced obesity in mice. Nat. Commun. 2022;13(1):2748. DOI:10.1038/s41467-022-30470-w.; Wang L., Gao T., Li Y., Xie Y., Zeng S., Tai C. et al. A long-term anti-infammation markedly alleviated high-fat diet-induced obesity by repeated administrations of overexpressing IL10 human umbilical cord-derived mesenchymal stromal cells. Stem Cell Res. Ther. 2022;13(1):259. DOI:10.1186/s13287-022-02935-8.; Hachiya R., Tanaka M., Itoh M., Suganami T. Molecular mechanism of crosstalk between immune and metabolic systems in metabolic syndrome. Infl amm. Regen. 2022;42(1):13. DOI:10.1186/s41232-022-00198-7.; Kawai T., Autieri M.V., Scalia R. Adipose tissue infl ammation and metabolic dysfunction in obesity. Am. J. Physiol. Cell Physiol. 2021;320(3):C375–C391. DOI:10.1152/ajpcell.00379.2020.; Криволапов Ю.А., Леенман Е.Е. Морфологическая диагностика лимфом. СПб: КОСТА; 2006:208.; Беспалова И.Д., Рязанцева Н.В., Калюжин В.В., Дзюман А.Н., Осихов И.А., Медянцев Ю.А. и др. Клинико-морфологические параллели при абдоминальном ожирении. Бюллетень Сибирского отделения Российской академии медицинских наук. 2014;34(4):51–58.; Zhang X., Liu Z., Li W., Kang Y., Xu Z., Li X. et al. MAPKs/AP-1, not NF-κB, is responsible for MCP-1 production in TNF-α-activated adipocytes. Adipocyte. 2022;11(1):477–486. DOI:10.1080/21623945.2022.2107786.; Nour O.A., Ghoniem H.A., Nader M.A., Suddek Gh.M. Impact of protocatechuic acid on high fat diet-induced metabolic syndrome sequelae in rats. European Journal of Pharmacology. 2021;907:174257. DOI:10.1016/j.ejphar.2021.174257.; Кологривова И.В., Суслова Т.Е., Кошельская О.А., Ребенкова М.С., Харитонова О.А., Андреев С.Л. и др. Макрофаги в эпикардиальной жировой ткани и сывороточный NT-proBNP у пациентов со стабильной ишемической болезнью сердца. Медицинская иммунология. 2022;24(2):389–394. DOI:10.15789/0000-0003-4049-8715.; Часовских Н.Ю., Рязанцева Н.В., Новицкий В.В. Апоптоз и окислительный стресс. Томск: Печатная мануфактура; 2009:148.; Иванов В.В., Шахристова Е.В., Степовая Е.А., Носарева О.Л., Фёдорова Т.С., Рязанцева Н.В. и др. Окислительный стресс: влияние на секрецию инсулина, рецепцию гормона адипоцитами и липолиз в жировой ткани. Бюллетень сибирской медицины. 2014;13(3):32–39. DOI:10.20538/1682-0363-2014-3-32-39.; Hotamisligil G.S. Endoplasmic reticulum stress and the infl ammatory basis of metabolic disease. Cell. 2010;140(6):900–917. DOI:10.1016/j.cell.2010.02.034.; https://cardiotomsk.elpub.ru/jour/article/view/1512

الاتاحة: https://cardiotomsk.elpub.ru/jour/article/view/1512
https://doi.org/10.29001/2073-8552-2022-37-3-114-120

المؤلفون: V. V. Kalyuzhin, A. T. Teplyakov, I. D. Bespalova, E. V. Kalyuzhina, N. N. Terentyeva, E. V. Grakova, K. V. Kopeva, V. Yu. Usov, N. P. Garganeeva, O. A. Pavlenko, Yu. V. Gorelova, A. V. Teteneva, В. В. Калюжин, А. Т. Тепляков, И. Д. Беспалова, Е. В. Калюжина, Н. Н. Терентьева, Е. В. Гракова, К. В. Копьева, В. Ю. Усов, Н. П. Гарганеева, О. А. Павленко, Ю. В. Горелова, А. В. Тетенева

المصدر: Bulletin of Siberian Medicine; Том 21, № 3 (2022); 181-197 ; Бюллетень сибирской медицины; Том 21, № 3 (2022); 181-197 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2022-21-3

مصطلحات موضوعية: имплантация аппарата вспомогательного кровообращения, treatment, neurohormonal modulators, sacubitril / valsartan, pecavaptan, fineron, vericiguat, sodium – glucose cotransporter type 2 inhibitors, omecamtiv mecarbil, gene therapy, cardiac resynchronization therapy, cardiac contractility modulation, heart transplantation, implantation of a circulatory assist device, лечение, нейрогормональные модуляторы, сакубитрил/валсартан, пекаваптан, финерон, верицигуат, ингибиторы натрий-глюкозного котранспортера 2-го типа, омекамтив мекарбил, генная терапия, сердечная ресинхронизирующая терапия, модуляция сердечной сократимости, трансплантация сердца

وصف الملف: application/pdf

Relation: https://bulletin.tomsk.ru/jour/article/view/4920/3267; McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021;42(36):3599−3726. DOI:10.1093/eurheartj/ehab368.; Salah H.M., Minhas A.M.K., Khan M.S., Khan S.U., Ambrosy A.P., Blumer V. et al. Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018. Am. Heart J. 2022; 243:103−109. DOI:10.1016/j.ahj.2021.09.009.; Roger V.L. Epidemiology of heart failure: A contemporary perspective. Circ. Res. 2021;128(10):1421−1434. DOI:10.1161/CIRCRESAHA.121.318172.; Калюжин В.В., Тепляков А.Т., Калюжин О.В. Сердеч ная недостаточность. М.: Медицинское информационное агентство, 2018:376.; Groenewegen A., Rutten F.H., Mosterd A., Hoes A.W. Epidemiology of heart failure. Eur. J. Heart Fail. 2020;22 (8):1342−1356. DOI:10.1002/ejhf.1858.; Тепляков А.Т., Тарасов Н.И., Исаков Л.К., Гракова Е.В., Синькова М.Н., Копьева К.В. и др. Прогноз сердечно-сосудистых событий после имплантации кардиовертера-дефибриллятора пациентам с хронической сердечной недостаточностью: значение повышения концентрации эндотелина-1 и растворимой формы белка ST2 в плазме крови. Бюллетень сибирской медицины. 2018;17(3):140−150. DOI:10.20538/1682-0363-2018-3-140-150.; Bottle A., Faitna P., Aylin P., Cowie M.R. Five-year survival and use of hospital services following ICD and CRT implantation: comparing real-world data with RCTs. ESC Heart Fail. 2021;8(4):2438−2447. DOI:10.1002/ehf2.13357.; Spitaleri G., Lupón J., Domingo M., Santiago-Vacas E., Codina P., Zamora E. et al. Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018. Sci. Rep. 2021;11(1):732. DOI:10.1038/s41598-020-79926-3.; Virani S.S., Alonso A., Aparicio H.J., Benjamin E.J., Bittencourt M.S., Callaway C.W. et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254−e743. DOI:10.1161/CIR.0000000000000950.; Поляков Д.С., Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Артемьева Е.Г. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА–ХСН. Кардиология. 2021;61(4):4−14. [DOI:10.18087/cardio.2021.4.n1628.; Remme W.J., Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 2001;22(17):1527–1560. DOI:10.1053/euhj.2001.2783.; Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбеко ва Ю.Л., Васюк Ю.А., Гарганеева А.А. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(S6):8−161. DOI:10.18087/cardio.2475.; Калюжин В.В., Тепляков А.Т., Черногорюк Г.Э., Калюжина Е.В., Беспалова И.Д., Терентьева Н.Н. и др. Хроническая сердечная недостаточность: синдром или заболевание? Бюллетень сибирской медицины. 2020;19(1):134–139. DOI:10.20538/1682-0363-2020-1-134–139.; Triposkiadis F., Xanthopoulos A., Parissis J., Butler J., Farmakis D. Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. Heart Fail. Rev. 2022;27(1):337−344. DOI:10.1007/s10741020-09987-z.; Fayol A., Wack M., Livrozet M., Carves J.B., Domengé O., Vermersch E. et al. Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction. ESC Heart Fail. 2022;9(1):519−530. DOI:10.1002/ehf2.13717.; Ройтберг Г.Е., Струтынский А.В. Внутренние болезни. Сердечно-сосудистая система: учеб. пособие. М.: МЕДпресс-информ, 2019:904.; Мареев В.Ю., Беленков Ю.Н. Перспективы в лечении хронической сердечной недостаточности. Журнал сердечная недостаточность. 2002;3(3):109–114.; Xanthopoulos A., Tryposkiadis K., Giamouzis G., Dimos A., Bourazana A., Papamichalis M. et al. Coexisting morbidity burden in hospitalized elderly patients with new-onset heart failure vs acutely decompensated chronic heart failure. Angiology. 2022;33197211062661. DOI:10.1177/00033197211062661.; Калюжин В.В., Тепляков А.Т., Беспалова И.Д., Калюжина Е.В., Останко В.Л., Терентьева Н.Н. и др. Корректная формулировка диагноза у пациента с хронической сердечной недостаточностью: реальность или несбыточная мечта? Бюллетень сибирской медицины. 2020;19(3):128−136. DOI:10.20538/1682-0363-2020-3-128-136.; Zheng C., Han L., Tian J., Li J., He H., Han G. et al. Hierarchical management of chronic heart failure: a perspective based on the latent structure of comorbidities. ESC Heart Fail. 2022;9(1):595−605. DOI:10.1002/ehf2.13708.; Maeda D., Matsue Y., Kagiyama N., Jujo K., Saito K., Kamiya K. et al. Inaccurate recognition of own comorbidities is associated with poor prognosis in elderly patients with heart failure. ESC Heart Fail. 2022. DOI:10.1002/ehf2.13824.; Kaye D., Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? Nat. Rev. Drug Discov. 2007;6:127– 139. DOI:10.1038/nrd2219.; Marra A.M., Bencivenga L., D’Assante R., Rengo G., Cittadini A. Heart failure with preserved ejection fraction: Squaring the circle between comorbidities and cardiovascular abnormalities. Eur. J. Intern. Med. 2022:S0953-6205(22)00018-8. DOI:10.1016/j.ejim.2022.01.019.; Sabouret P., Attias D., Beauvais C., Berthelot E., Bouleti C., Gibault Genty G. et al. Diagnosis and management of heart failure from hospital admission to discharge: A practical expert guidance. Ann. Cardiol. Angeiol. (Paris). 2022;71(1):41−52. DOI:10.1016/j.ancard.2021.05.004.; Ghionzoli N., Gentile F., Del Franco A.M., Castiglione V., Aimo A., Giannoni A. et al. Current and emerging drug targets in heart failure treatment. Heart Fail. Rev. 2021;27(4):1119– 1136. DOI:10.1007/s10741-021-10137-2.; Swedberg K. Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. Eur. J. Heart Fail. 2000;2(3):229−233. DOI:10.1016/s1388-9842(00)00102-1.; Калюжин В.В., Тепляков А.Т., Соловцов М.А. Роль систолической и диастолической дисфункции ЛЖ в клинической манифестации хронической сердечной недостаточности у больных, перенесших инфаркт миокарда. Терапевтический архив. 2002;74(12):15−18.; Калюжин В.В., Тепляков А.Т., Вечерский Ю.Ю., Рязанцева Н.В., Хлапов А.П. Патогенез хронической сердечной недостаточности: изменение доминирующей парадигмы. Бюллетень сибирской медицины. 2007;6(4):71−79. DOI:10.20538/1682-0363-2007-4-71-79.; Калюжин В.В., Тепляков А.Т., Рязанцева Н.В., Вечерский Ю.Ю., Хлапов А.П., Колесников Р.Н. Диастола сердца. Физиология и клиническая патофизиология. Томск: Изд-во ТПУ, 2007:212.; Gheorghiade M., De Luca L., Bonow R.O. Neurohormonal inhibition in heart failure: insights from recent clinical trials. Am. J. Cardiol. 2005;96(12A):3L−9L. DOI:10.1016/j.amjcard.2005.09.059.; Тепляков А.Т., Попов С.В., Калюжин В.В., Гарганеева А.А., Курлов И.О., Нилогов В.Л. и др. Оценка влияния карведилола, атенолола и их комбинации с фозиноприлом на вариабельность ритма сердца, клинико-функциональный статус и качество жизни больных с постинфарктной дисфункцией левого желудочка. Терапевтический архив. 2004;76(9):62−65.; Jneid H., Moukarbel G.V., Dawson B., Hajjar R.J., Francis G.S. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy. Am. J. Med. 2007;120(12):1090. e1−1090.e8. DOI:10.1016/j.amjmed.2007.02.029.; Dobrek Ł., Thor P. Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy. Acta Pol. Pharm. 2011;68(3):307−316.; Ferrari R., Cardoso J., Fonseca M.C., Aguiar C., Moreira J.I., Fucili A. et al. ARNIs: balancing “the good and the bad” of neuroendocrine response to HF. Clin. Res. Cardiol. 2020;109(5):599−610. DOI:10.1007/s00392-019-01547-2.; Berliner D., Bauersachs J. New drugs: big changes in conservative heart failure therapy? Eur. J. Cardiothorac. Surg. 2019;55(1):i3−i10. DOI:10.1093/ejcts/ezy421.; Gu J., Noe A., Chandra P., Al-Fayoumi S., Ligueros-Say lan M., Sarangapani R. et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J. Clin. Pharmacol. 2010;50(4):401−414. DOI:10.1177/0091270009343932.; McMurray J.J., Packer M., Desai A.S., Gong J., Lefko witz M.P., Rizkala A.R. et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur. J. Heart Fail. 2013;15(9):1062−1073. DOI:10.1093/eurjhf/hft052.; Berg D.D., Samsky M.D., Velazquez E.J., Duffy C.I., Gurmu Y., Braunwald E. et al. Efficacy and Safety of Sacubitril/ Valsartan in High-Risk Patients in the PIONEER-HF Trial. Circ. Heart Fail. 2021;14(2):e007034. DOI:10.1161/CIRCHEARTFAILURE.120.007034.; Wachter R., Senni M., Belohlavek J., Straburzynska-Migaj E., Witte K.K., Kobalava Z. et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur. J. Heart Fail. 2019; 21 (8):998−1007. DOI:10.1002/ejhf.1498; Chandra A., Lewis E.F., Claggett B.L., Desai A.S., Packer M., Zile M.R. et al. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018;3(6):498−505. DOI:10.1001/jamacardio.2018.0398.; Lindenfeld J., Jessup M. ‘Drugs don’t work in patients who don’t take them’ (C. Everett Koop, MD, US Surgeon General, 1985). Eur. J. Heart Fail. 2017;19(11):1412−1413. DOI:10.1002/ejhf.920.; Cole G.D., Patel S.J., Zaman N., Barron A.J., Raphael C.E., Mayet J. et al. “Triple therapy” of heart failure with angiotensin-converting enzyme inhibitor, beta-blocker, and aldosterone antagonist may triple survival time: shouldn’t we tell patients? JACC Heart Fail. 2014;2(5):545−548. DOI:10.1016/j.jchf.2014.04.012/; Zaman S., Zaman S.S., Scholtes T., Shun-Shin M.J., Plymen C.M., Francis D.P., Cole G.D. The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. Eur. J. Heart Fail. 2017;19(11):1401−1409. DOI:10.1002/ejhf.838.; Bhatt A.S., Vaduganathan M., Claggett B.L., Liu J. Packer M., Desai A.S. et al. Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur. J. Heart Fail. 2021;23(9):1518−1524. DOI:10.1002/ejhf.2259.; Cabral J., Vasconcelos H., Maia-Araújo P., Moreira E., Campelo M., Amorim S. et al Sacubitril/valsartan in everyday clinical practice: an observational study based on the experience of a heart failure clinic. Cardiovasc. Diagn. Ther. 2021;11(6):1217−1227. DOI:10.21037/cdt-21-312.; Yoshikawa T. New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading? J. Cardiol. 2022:S0914-5087(22)00031-4. DOI:10.1016/j.jjcc.2022.02.008.; Мареев Ю.В., Мареев В.Ю. Возможности современной терапии в улучшении прогноза при хронической сердечной недостаточности: фокус на ангиотензиновых рецепторов и неприлизина ингибиторах и ингибиторах натрий глюкозного транспортера. Кардиология. 2021;61(6):4−10. DOI:10.18087/cardio.2021.6.n1678.; Vaduganathan M., Claggett B.L., Greene S.J., Aggarwal R., Bhatt A.S., McMurray J.J.V. et al. Potential implications of expanded US food and drug administration labeling for sacubitril/ valsartan in the US. JAMA Cardiol. 2021;6(12):1415−1423. DOI:10.1001/jamacardio.2021.3651.; Lin Y., Wu M., Liao B., Pang X., Chen Q., Yuan J. et al. Comparison of Pharmacological Treatment Effects on Long-Time Outcomes in Heart Failure With Preserved Ejection Fraction: A Network Meta-analysis of Randomized Controlled Trials. Front. Pharmacol. 2021;12:707777. DOI:10.3389/fphar.2021.707777.; Bozkurt B., Ezekowitz J. Substance and Substrate: LVEF and Sex Subgroup Analyses of PARAGON-HF and PARADIGM-HF Trials. Circulation. 2020;141(5):362−366. DOI:10.1161/CIRCULATIONAHA.120.045008; Yancy C.W. An expanded heart failure indication for sacubitril/valsartan: evolving the evidence bar. JAMA Cardiol. 2021;6(12):1357−1358. DOI:10.1001/jamacardio.2021.3658.; Gallo G., Volpe M., Battistoni A., Russo D., Tocci G., Musumeci M.B. Sacubitril/valsartan as a therapeutic tool across the range of heart failure phenotypes and ejection fraction spectrum. Front. Physiol. 2021;12:652163. DOI:10.3389/fphys.2021.652163.; Vaz-Salvador P., Adão R., Vasconcelos I., Leite-Moreira A.F., Brás-Silva C. Heart failure with preserved ejection fraction: a pharmacotherapeutic update. Cardiovasc. Drugs Ther. 2022:1–18. DOI:10.1007/s10557-021-07306-8.; Aikins A.O., Nguyen D.H., Paundralingga O., Farmer G.E., Shimoura C.G., Brock C. et al. Cardiovascular neuroendocrinology: emerging role for neurohypophyseal hormones in pathophysiology. Endocrinology. 2021;162(8):bqab082. DOI:10.1210/endocr/bqab082.; Urbach J., Goldsmith S.R. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials. Ther. Adv. Cardiovasc. Dis. 2021;15:1753944720977741. DOI:10.1177/1753944720977741.; Vishram-Nielsen J.K.K., Tomasoni D., Gustafsson F., Metra M. Contemporary drug treatment of advanced heart failure with reduced ejection fraction. Drugs. 2022:1−31. DOI:10.1007/s40265-021-01666-z.; Bhatt A.S., Yanamandala M., Konstam M.A. For vaptans, as for life, balance is better. Eur. J. Heart Fail. 2021;23(5):751−753. DOI:10.1002/ejhf.2042.; Goldsmith S.R., Burkhoff D., Gustafsson F., Voors A., Zannad F., Kolkhof P. et al. Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. J. Card. Fail. 2021;27(2):233−241. DOI:10.1016/j.cardfail.2020.10.007.; Mondritzki T., Mai T.A., Vogel J., Pook E., Wasnaire P., Schmeck C. et al. Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure. Eur. J. Heart Fail. 2021;23(5):743−750. DOI:10.1002/ejhf.2001.; Kolkhof P., Bärfacker L. 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J. Endocrinol. 2017;234(1):T125− T140. DOI:10.1530/JOE-16-0600.; Filippatos G., Anker S.D., Böhm M., Gheorghiade M., Køber L., Krum H. et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur. Heart J. 2016;37(27):2105−2114. DOI:10.1093/eurheartj/ehw132.; Capelli I., Gasperoni L., Ruggeri M., Donati G., Baraldi O., Sorrenti G. et al. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure. J. Nephrol. 2020;33(1):37−48. DOI:10.1007/s40620-01900600-7.; Rico-Mesa J.S., White A., Ahmadian-Tehrani A., Anderson AS. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone. Curr. Cardiol. Rep. 2020;22(11):140. DOI:10.1007/s11886-020-01399-7.; Filippatos G., Anker S.D., Agarwal R., Ruilope L.M., Rossing P., Bakris G.L. et al. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022;145(6):437−447. DOI:10.1161/CIRCULATIONAHA.121.057983.; Cox Z.L., Hung R., Lenihan D.J., Testani J.M. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3t trial. JACC Heart Fail. 2020;8(3):157−168. DOI:10.1016/j.jchf.2019.09.012.; Batool A., Salehi N., Chaudhry S., Cross M., Malkawi A., Siraj A. Role of vasodilator therapy in acute heart failure. Cureus. 2021;13(8):e17126. DOI:10.7759/cureus.17126.; Armstrong P.W., Pieske B., Anstrom K.J., Ezekowitz J., Hernandez A.F., Butler J. et al. Vericiguat in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 2020;382(20):1883−1893. DOI:10.1056/NEJMoa1915928.; Calamera G., Moltzau L.R., Levy F.O., Andressen K.W. Phosphodiesterases and compartmentation of cAMP and cGMP signaling in regulation of cardiac contractility in normal and failing hearts. Int. J. Mol. Sci. 2022;23(4):2145. DOI:10.3390/ijms23042145.; Klinger J.R., Chakinala M.M., Langleben D., Rosenkranz S., Sitbon O. Riociguat: clinical research and evolving role in therapy. Br. J. Clin. Pharmacol. 2021;87(7):2645−2662. DOI:10.1111/bcp.14676.; McMurray J.J.V., Solomon S.D., Inzucchi S.E., Køber L., Kosiborod M.N., Martinez F.A. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 2019;381(21):1995−2008. DOI:10.1056/NEJMoa1911303.; Packer M., Anker S.D., Butler J., Filippatos G., Poco ck S.J., Carson P. et al. Cardiovascular and renal out comes with empagliflozin in heart failure. N. Engl. J. Med. 2020;383(15):1413−1424. DOI:10.1056/NEJMoa2022190.; Solomon S.D., de Boer R.A., DeMets D., Hernandez A.F., Inzucchi S.E., Kosiborod M.N. et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur. J. Heart Fail. 2021;23(7):1217−1225. DOI:10.1002/ejhf.2249.; Butler J., Packer M., Filippatos G., Ferreira J.P., Zeller C., Schnee J. et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur. Heart J. 2022;43(5):416−426. DOI:10.1093/eurheartj/ehab798.; Yadava O.P. Heart failure does ejection fraction hold any relevance? Indian J. Thorac. Cardiovasc. Surg. 2022;38(1):1−4. DOI:10.1007/s12055-021-01295-x.; Bethel M.A., McMurray J.J.V. Class effect for sodium glucose-cotransporter-2 inhibitors in cardiovascular outcomes: implications for the cardiovascular disease specialist. Circulation. 2018;137(12):1218−1220. DOI:10.1161/CIRCULATIONAHA.117.030117.; Volpe M., Patrono C. Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors? Eur. Heart J. 2020;41(44):4232−4233. DOI:10.1093/eurheartj/ehaa891.; Teo Y.H., Yoong C.S.Y., Syn N.L., Teo Y.N., Cheong J.Y.A., Lim Y.C. et al. Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials. Eur. J. Clin. Pharmacol. 2021;77(10):1453−1464. DOI:10.1007/s00228-02103147-4.; Savarese G., Butler J., Lund L.H., Bhatt D.L., Anker S.D. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovasc. Res. 2021:cvab271. DOI:10.1093/cvr/cvab271.; Täger T., Frankenstein L., Atar D., Agewall S., Frey N., Grundtvig M. et al. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Clin. Res. Cardiol. 2022;111(4):428– 439. DOI:10.1007/s00392-021-01913-z.; Correale M., Lamacchia O., Ciccarelli M., Dattilo G., Tricarico L., Brunetti N.D. Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients. Heart Fail. Rev. 2021. DOI:10.1007/s10741-021-10157-y.; Helmstädter J., Keppeler K., Küster L., Münzel T., Daiber A., Steven S. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor. Br. J. Pharmacol. 2022;179(4):659−676. DOI:10.1111/bph.15462.; Tanday N., Flatt P.R., Irwin N. Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands. Br. J. Pharmacol. 2022;179(4):526−541. DOI:10.1111/bph.15485.; Rashki Kemmak A., Dolatshahi Z., Mezginejad F., Narge si S. Economic evaluation of ivabradine in treatment of patients with heart failure: a systematic review. Expert Rev. Pharmacoecon. Outcomes Res. 2022;22(1):37−44. DOI:10.1080/14737167.2021.1941881.; Heringlake M., Alvarez J., Bettex D., Bouchez S., Fruhwald S., Girardis M. et al. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert Rev. Cardiovasc. Ther. 2021;19(4):325−335. DOI:10.1080/14779072.2021.1905520.; Asai Y., Sato T., Kito D., Yamamoto T., Hioki I., Urata Y. et al. Combination therapy of midodrine and droxidopa for refractory hypotension in heart failure with preserved ejection fraction per a pharmacist’s proposal: a case report. J. Pharm. Health Care Sci. 2021;7(1):10. DOI:10.1186/s40780-02100193-z.; Nagao K., Kato T., Yaku H., Morimoto T., Inuzuka Y., Tamaki Y. et al. Current use of inotropes according to initial blood pressure and peripheral perfusion in the treatment of congestive heart failure: findings from a multicentre observational study. BMJ Open. 2022;12(1):e053254. DOI:10.1136/bmjopen-2021-053254.; Cotter G., Davison B.A., Edwards C., Takagi K., Cohen-Solal A., Mebazaa A. Acute heart failure treatment: a light at the end of the tunnel? Eur. J. Heart Fail. 2021;23(5):698−702. DOI:10.1002/ejhf.2116.; Felker G.M., Solomon S.D., Claggett B., Diaz R., McMurray J.J.V., Metra M. et al. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. JAMA Cardiol. 2022;7(1):26−34. DOI:10.1001/jamacardio.2021.4027.; Bernardo B.C., Blaxall B.C. From bench to bedside: new approaches to therapeutic discovery for heart failure. Heart Lung Circ. 2016;25(5):425−434. DOI:10.1016/j.hlc.2016.01.002.; Greenberg B. Gene therapy for heart failure. Trends Cardiovasc. Med. 2017;27(3):216−222. DOI:10.1016/j.tcm.2016.11.001.; Gabisonia K., Recchia F.A. Gene therapy for heart failure: new perspectives. Curr. Heart Fail. Rep. 2018;15(6):340−349. DOI:10.1007/s11897-018-0410-z.; Yamada K.P., Tharakan S., Ishikawa K. Consideration of clinical translation of cardiac AAV gene therapy. Cell Gene Ther. Insights. 2020;6(5):609−615. DOI:10.18609/cgti.2020.073.; Devarakonda T., Mauro A.G., Cain C., Das A., Salloum F.N. Cardiac gene therapy with relaxin receptor 1 overexpression protects against acute myocardial infarction. JACC Basic Transl. Sci. 2021;7(1):53−63. DOI:10.1016/j.jacbts.2021.10.012.; Sayed N., Allawadhi P., Khurana A., Singh V., Navik U., Pasumarthi S.K. et al. Gene therapy: comprehensive overview and therapeutic applications. Life Sci. 2022;294:120375. DOI:10.1016/j.lfs.2022.120375.; Palmiero G., Florio M.T., Rubino M., Nesti M., Marchel M., Russo V. Cardiac resynchronization therapy in patients with heart failure: what is new? Heart Fail. Clin. 2021;17(2):289−301. DOI:10.1016/j.hfc.2021.01.010.; Heidenreich P.A., Bozkurt B., Aguilar D., Allen L.A., Byun J.J., Colvin M.M. et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022:101161CIR0000000000001062. DOI:10.1161/CIR.0000000000001062.; Chinyere I.R., Balakrishnan M., Hutchinson M.D. The emerging role of cardiac contractility modulation in heart failure treatment. Curr. Opin. Cardiol. 2022;37(1):30−35. DOI:10.1097/HCO.0000000000000929.; Jorbenadze A., Fudim M., Mahfoud F., Adamson P.B., Bekfani T., Wachter R. et al. Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies. ESC Heart Fail. 2021;8(4):3327−3338. DOI:10.1002/ehf2.13361.; Reed S.D., Yang J.C., Rickert T., Johnson F.R., Gonzalez J.M., Mentz R.J. et al. Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study. Circ. Heart Fail. 2022;15(1):e008797. DOI:10.1161/CIRCHEARTFAILURE.121.008797.; Baumwol J. “I Need Help” − A mnemonic to aid timely referral in advanced heart failure. J. Heart Lung Transplant. 2017;36(5):593594. DOI:10.1016/j.healun.2017.02.010.; Калюжин В.В., Тепляков А.Т., Беспалова И.Д., Калюжина Е.В., Терентьева Н.Н., Сибирева О.Ф. et al. Прогрессирующая (advanced) сердечная недостаточность. Бюллетень сибирской медицины. 2021;20(1):129−146. DOI:10.20538/1682-0363-2021-1-129-146.; Crespo-Leiro M.G., Metra M., Lund L.H., Milicic D., Costanzo M.R., Filippatos G. et al. Advanced heart fail ure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2018;20(11):1505−1535. DOI:10.1002/ejhf.1236.; Shi X., Bao J., Zhang H., Wang H., Li L., Zhang Y. Patients with high-dose diuretics should get ultrafiltration in the management of decompensated heart failure: a meta-analysis. Heart Fail. Rev. 2019;24(6):927−940. DOI:10.1007/s10741-019-09812-2.; Grossekettler L., Schmack B., Meyer K., Brockmann C., Wanninger R., Kreusser M.M. et al. Peritoneal dialysis as therapeutic option in heart failure patients. ESC Heart Fail. 2019;6(2):271−279. DOI:10.1002/ehf2.12411.; Masarone D., Kittleson M., Petraio A., Pacileo G. Advanced heart failure: state of the art and future directions. Rev. Cardiovasc. Med. 2022;23(2):48. DOI:10.31083/j.rcm2302048.; Hullin R., Meyer P., Yerly P., Kirsch M. Cardiac surgery in advanced heart failure. J. Clin. Med. 2022;11(3):773. DOI:10.3390/jcm11030773.; Tadic M., Sala C., Cuspidi C. The role of TAVR in patients with heart failure: do we have the responses to all questions? Heart Fail. Rev. 2022;27:1617–1625. DOI:10.1007/s10741021-10206-6.; Yousef S., Arnaoutakis G.J., Gada H., Smith A.J.C., Sanon S., Sultan I. Transcatheter mitral valve therapies: State of the art. J. Card. Surg. 2022;37(1):225−233. DOI:10.1111/jocs.15995.; Lund L.H., Khush K.K., Cherikh W.S., Goldfarb S., Kucheryavaya A.Y., Levvey B.J. et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus Theme: Allograft ischemic time. J. Heart Lung Transplant. 2017;36(10):1037−1046. DOI:10.1016/j.healun.2017.07.019.; Kormos R.L., Cowger J., Pagani F.D., Teuteberg J.J., Goldstein D.J., Jacobs J.P. et al. The society of thoracic surgeons intermacs database annual report: evolving indications, outcomes, and scientific partnerships. Ann. Thorac. Surg. 2019;107(2):341−353. DOI:10.1016/j.athoracsur.2018.11.011.; Rizzo C., Carbonara R., Ruggieri R., Passantino A., Scrutinio D. Iron deficiency: a new target for patients with heart failure. Front. Cardiovasc. Med. 2021;8:709872. DOI:10.3389/fcvm.2021.709872.; Мареев В.Ю., Гиляревский С.Р., Мареев Ю.В., Беграмбекова Ю.Л., Беленков Ю.Н., Васюк Ю.А. и др. Согласованное мнение экспертов по поводу роли дефицита железа у больных с хронической сердечной недостаточностью, а также о современных подходах к его коррекции. Кардиология. 2020;60(1):99−106. DOI:10.18087/cardio.2020.1.n961.; Pintér A., Behon A., Veres B., Merkel E.D., Schwertner W.R., Kuthi L.K. et al. The prognostic value of anemia in patients with preserved, mildly reduced and recovered ejection fraction. Diagnostics (Basel). 2022;12(2):517. DOI:10.3390/diagnostics12020517.; Toblli J.E., Brignoli R. Iron(III)-hydroxide polymaltose complex in iron deficiency anemia / review and meta-analysis. Arzneimittelforschung. 2007;57(6A):431−438. DOI:10.1055/s-0031-1296692.; Zdravkovic S.C., Nagorni S.P., Cojbasic I., Mitic V., Cvetkovic P., Nagorni I. et al. Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure. J. Int. Med. Res. 2019;47(7):3179−3189. DOI:10.1177/0300060519847352.; Loncar G., Obradovic D., Thiele H., von Haehling S., Lainscak M. Iron deficiency in heart failure. ESC Heart Fail. 2021;8(4):2368−2379. DOI:10.1002/ehf2.13265.; Shen T., Xia L., Dong W., Wang J., Su F., Niu S. et al. A Systematic Review and Meta-Analysis: Safety and Efficacy of Mesenchymal Stem Cells Therapy for Heart Failure. Curr. Stem Cell Res. Ther. 2021;16(3):354−365. DOI:10.2174/1574888X15999200820171432.; Kir D., Patel M.J., Munagala M.R. What is the status of regenerative therapy in heart failure? Curr. Cardiol. Rep. 2021;23(10):146. DOI:10.1007/s11886-021-01575-3.; Pourtaji A., Jahani V., Moallem S.M.H., Karimani A., Mohammadpour A.H. Application of G-CSF in congestive heart failure treatment. Curr. Cardiol. Rev. 2019;15(2):83−90. DOI:10.2174/1573403X14666181031115118; Sadahiro T., Ieda M. In vivo reprogramming as a new approach to cardiac regenerative therapy. Semin. Cell Dev. Biol. 2022;122:21−27. DOI:10.1016/j.semcdb.2021.06.019.; Testa G., Di Benedetto G., Passaro F. Advanced Technologies to Target Cardiac Cell Fate Plasticity for Heart Regeneration. Int. J. Mol. Sci. 2021;22(17):9517. DOI:10.3390/ijms22179517; Pascale E., Caiazza C., Paladino M., Parisi S., Passa ro F., Caiazzo M. MicroRNA Roles in Cell Reprogramming Mechanisms. Cells. 2022;11(6):940. DOI:10.3390/cells11060940; Zhou W., Ma T., Ding S. Non-viral approaches for somat ic cell reprogramming into cardiomyocytes. Semin. Cell Dev. Biol. 2022;122:28−36. DOI:10.1016/j.semcdb.2021.06.021; Garbern J.C., Lee R.T. Heart regeneration: 20 years of progress and renewed optimism. Dev. Cell. 2022;57(4):424−439. DOI:10.1016/j.devcel.2022.01.012.; Sharma V., Dash S.K., Govarthanan K., Gahtori R., Negi N., Barani M. et al. Recent advances in cardiac tissue engineering for the management of myocardium infarction. Cells. 2021;10(10):2538. DOI:10.3390/cells10102538.; Goonoo N. Tunable biomaterials for myocardial tissue regeneration: promising new strategies for advanced biointerface control and improved therapeutic outcomes. Biomater. Sci. 2022;10(7):1626−1646. DOI:10.1039/d1bm01641e.; Hoeeg C., Dolatshahi-Pirouz A., Follin B. Injectable hydrogels for improving cardiac cell therapy in vivo evidence and translational challenges. Gells. 2021;7(1):7. DOI:10.3390/gels7010007.; Eschenhagen T., Ridders K., Weinberger F. How to repair a broken heart with pluripotent stem cell-derived cardiomyocytes. J. Mol. Cell. Cardiol. 2022;163:106−117. DOI:10.1016/j.yjmcc.2021.10.005.; Калюжин В.В., Соловцов М.А., Камаев Д.Ю. Эффективность цитокардиопротекции у больных с умеренно выраженной постинфарктной дисфункцией левого желудочка: результаты рандомизированного исследования триметазидина и атенолола. Бюллетень сибирской медицины. 2002;1(1):40−44. DOI:10.20538/1682-03632002-1-40-44.; Shu H., Peng Y., Hang W., Zhou N., Wang D.W. Trimetazidine in heart failure. Front. Pharmacol. 2021;11:569132. DOI:10.3389/fphar.2020.569132.; Jong C.J., Sandal P., Schaffer S.W. The role of taurine in mitochondria health: more than just an antioxidant. Molecules. 2021;26(16):4913. DOI:10.3390/molecules26164913.; Yuan S., Schmidt H.M., Wood K.C., Straub A.C. Coenzyme Q in cellular redox regulation and clinical heart failure. Free Radic. Biol. Med. 2021;167:321−334. DOI:10.1016/j.freeradbiomed.2021.03.011.; Raddysh M.E., Delgado D.H. Integratingsupplementationinthe management of patients with heart failure: an evidence-based review. Expert. Rev. Cardiovasc. Ther. 2021;19(10):891−905. DOI:10.1080/14779072.2021.1999806.; Oppedisano F., Mollace R., Tavernese A., Gliozzi M., Musolino V., Macrì R. et al. PUFA supplementation and heart failure: effects on fibrosis and cardiac remodeling. Nutrients. 2021;13(9):2965. DOI:10.3390/nu13092965.; Liu J., Meng Q., Zheng L., Yu P., Hu H., Zhuang R. et al. Effect of omega-3 polyunsaturated fatty acids on left ventricular remodeling in chronic heart failure: a systematic review and meta-analysis. Br. J. Nutr. 2022;1−35. DOI:10.1017/S0007114521004979.; Мареев В.Ю., Мареев Ю.В., Беграмбекова Ю.Л. Коэнзим Q-10 в лечении больных с хронической сердечной недостаточностью и сниженной фракцией выброса левого желудочка: систематический обзор и мета-анализ. Кардиология. 2022;62(6):3−14. DOI:10.18087/cardio.2022.6.n2050.; Samuel T.Y., Hasin T., Gotsman I., Weitzman T., Ben Ivgi F., Dadon Z. et al. Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Drugs R. D. 2022;22(1):25−33. DOI:10.1007/s40268-02100372-1.; Mongirdienė A., Skrodenis L., Varoneckaitė L., Mierkytė G., Gerulis J. Reactive oxygen species induced pathways in heart failure pathogenesis and potential therapeutic strategies. Biomedicines. 2022;10(3):602. DOI:10.3390/biomedicines10030602.; Schwemmlein J., Maack C., Bertero E. Mitochondria as therapeutic targets in heart failure. Curr. Heart Fail. Rep. 2022;19(2):27–36. DOI:10.1007/s11897-022-00539-0.; Bisaccia G., Ricci F., Gallina S., Di Baldassarre A., Ghinassi B. Mitochondrial Dysfunction and Heart Disease: Critical Appraisal of an Overlooked Association. Int. J. Mol. Sci. 2021;22(2):614. DOI:10.3390/ijms22020614.; Ghionzoli N., Gentile F., Del Franco A.M., Castiglione V., Aimo A., Giannoni A. et al. Current and emerging drug targets in heart failure treatment. Heart Fail. Rev. 2022;27(4):1119– 1136. DOI:10.1007/s10741-021-10137-2.; Ismail U., Sidhu K., Zieroth S. Hyperkalaemia in heart failure. Card. Fail. Rev. 2021;7:e10. DOI:10.15420/cfr.2020.29.; Murphy D., Ster I.C., Kaski J.C., Anderson L., Banerjee D. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure. BMC Nephrol. 2021;22(1):254. DOI:10.1186/s12882-021-02439-2; Montagnani A., Frasson S., Gussoni G., Manfellotto D. Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis. J. Clin. Med. 2021;10(23):5483. DOI:10.3390/jcm10235483.; Silva-Cardoso J., Brito D., Frazão J.M., Ferreira A., Bettencourt P., Branco P. et al. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease. Heart Fail. Rev. 2021;26(4):891−896. DOI:10.1007/s10741-02010069-3.; Останко В.Л., Калачева Т.П., Калюжина Е.В., Лившиц И.К., Шаловай А.А., Черногорюк Г.Э. и др. Биологические маркеры в стратификации риска развития и прогрессирования сердечно-сосудистой патологии: настоящее и будущее. Бюллетень сибирской медицины. 2018;17(4):264−280. DOI:10.20538/1682-0363-2018-4-264-280.; Sainio A., Järveläinen H. Extracellular matrix macromolecules as potential targets of cardiovascular pharmacotherapy. Adv. Pharmacol. 2018;81:209−240. DOI:10.1016/bs.apha.2017.09.008.; Castiglione V., Aimo A., Vergaro G., Saccaro L., Passi no C., Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail. Rev. 2022;27(2):625−643. DOI:10.1007/s10741-021-10105-w.; Sygitowicz G., Maciejak-Jastrzębska A., Sitkiewicz D. The diagnostic and therapeutic potential of galectin-3 in cardiovascular diseases. Biomolecules. 2021;12(1):46. DOI:10.3390/biom12010046.; Shirakawa K., Sano M. Osteopontin in cardiovascular diseases. Biomolecules. 2021;11(7):1047. DOI:10.3390/ biom11071047.; Maruyama K., Imanaka-Yoshida K. The pathogenesis of Cardiac Fibrosis: A Review of Recent Progress. Int. J. Mol. Sci. 2022;23(5):2617. DOI:10.3390/ijms23052617.; Aimo A., Spitaleri G., Panichella G., Lupón J., Emdin M., Bayes-Genis A. Pirfenidone as a novel cardiac protective treatment. Heart Fail. Rev. 2022;27(2):525−532. DOI:10.1007/s10741-021-10175-w.; Trinh K., Julovi S.M., Rogers N.M. The role of matrix proteins in cardiac pathology. Int. J. Mol. Sci. 2022;23(3):1338. DOI:10.3390/ijms23031338.; May B.M., Pimentel M., Zimerman L.I., Rohde L.E. GDF-15 as a biomarker in cardiovascular disease. Arq. Bras. Cardiol. 2021;116(3):494−500. DOI:10.36660/abc.20200426 .; Lewis G.A., Rosala-Hallas A., Dodd S., Schelbert E.B., Williams S.G., Cunnington C. et al. Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction. Int. J. Cardiovasc. Imaging. 2022. DOI:10.1007/s10554-022-02544-9.; Zhang Y., Bauersachs J., Langer H.F. Immune mechanisms in heart failure. Eur. J. Heart Fail. 2017;19(11):1379−1389. DOI:10.1002/ejhf.942.; Murphy S.P., Kakkar R., McCarthy C.P., Januzzi J.L. Jr. Inflammation in Heart Failure: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020;75(11):1324−1340. DOI:10.1016/j.jacc.2020.01.014.; Kumar P., Lim A., Poh S.L., Hazirah S.N., Chua C.J.H., Sutamam N.B. et al. Pro-Inflammatory Derangement of the Immuno-Interactome in Heart Failure. Front. Immunol. 2022;13:817514. DOI:10.3389/fimmu.2022.817514.; Bertero E., Dudek J., Cochain C., Delgobo M., Ramos G., Gerull B. et al. Immuno-metabolic interfaces in cardiac disease and failure. Cardiovasc. Res. 2022;118(1):37−52. DOI:10.1093/cvr/cvab036.; Everett B.M., Cornel J.H., Lainscak M., Anker S.D., Abbate A., Thuren T. et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019;139(10):1289−1299. DOI:10.1161/CIRCULATIONAHA.118.038010.; Abbate A., Toldo S., Marchetti C., Kron J., Van Tassell B.W., Dinarello C.A. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ. Res. 2020;126(9):1260−1280. DOI:10.1161/CIRCRESAHA.120.315937.; Hanna A., Frangogiannis N.G. Inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc. Drugs Ther. 2020;34(6):849−863. DOI:10.1007/s10557-020-07071-0.; Libby P. Targeting inflammatory pathways in cardiovascular disease: the inflammasome, interleukin-1, interleukin-6 and beyond. Cells. 2021;10(4):951. DOI:10.3390/cells10040951.; Reina-Couto M., Pereira-Terra P., Quelhas-Santos J., Silva-Pereira C., Albino-Teixeira A., Sousa T. Inflammation in human heart failure: major mediators and therapeutic targets. Front. Physiol. 2021Oct.11;12: 746494. DOI:10.3389/fphys.2021.746494; Szabo T.M., Frigy A., Nagy E.E. Targeting mediators of inflammation in heart failure: a short synthesis of experimental and clinical results. Int. J. Mol. Sci. 2021;22(23):13053. DOI:10.3390/ijms222313053.; Olsen M.B., Gregersen I., Sandanger Ø., Yang K., Sokolova M., Halvorsen B.E. et al. Targeting the inflammasome in cardiovascular disease. JACC Basic Transl. Sci. 2021;7(1):84−98. DOI:10.1016/j.jacbts.2021.08.006.; Ridker P.M., Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ. Res. 2021;128(11):1728−1746. DOI:10.1161/CIRCRESAHA.121.319077.; Corcoran S.E., Halai R., Cooper M.A. Pharmacological inhibition of the nod-like receptor family pyrin domain containing 3 inflammasome with MCC950. Pharmacol. Rev. 2021;73(3):968−1000. DOI:10.1124/pharmrev.120.000171/; Zhuang C., Chen R., Zheng Z., Lu J., Hong C. Toll-like receptor 3 in cardiovascular diseases. Heart Lung Circ. 2022:S14439506(22)00080-4. DOI:10.1016/j.hlc.2022.02.012.; Zhang F.S., He Q.Z., Qin C.H., Little P.J., Weng J.P., Xu S.W. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacol. Sin. 2022;43(9):2173–2190. DOI:10.1038/s41401-021-00835-w.; Arfè A., Scotti L., Varas-Lorenzo C., Nicotra F., Zambon A., Kollhorst B. et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;354:i4857. DOI:10.1136/bmj.i4857.; Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность. 2013;14(7):379–472.; https://bulletin.tomsk.ru/jour/article/view/4920

الاتاحة: https://bulletin.tomsk.ru/jour/article/view/4920
https://doi.org/10.20538/1682-0363-2022-3-181-197

المؤلفون: V. V. Kalyuzhin, A. T. Teplyakov, I. D. Bespalova, E. V. Kalyuzhina, N. N. Terentyeva, I. K. Livshits, V. L. Ostanko, E. V. Grakova, K. V. Kopeva, V. Yu. Usov, N. P. Garganeeva, Yu. V. Gorelova, В. В. Калюжин, А. Т. Тепляков, И. Д. Беспалова, Е. В. Калюжина, Н. Н. Терентьева, И. К. Лившиц, В. Л. Останко, Е. В. Гракова, К. В. Копьева, В. Ю. Усов, Н. П. Гарганеева, Ю. В. Горелова

المصدر: Bulletin of Siberian Medicine; Том 21, № 2 (2022); 152-167 ; Бюллетень сибирской медицины; Том 21, № 2 (2022); 152-167 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2022-21-2

مصطلحات موضوعية: ультрафильтрация, diuretic resistance, terminology, mechanisms, water and salt restriction, sequential nephron blockade, gliflozines, vaptans, inotropes, vasoconstrictors, glucocorticoids, serelaxin, nesiritide, albumin, ultrafiltration, резистентность к диуретикам, терминология, механизмы, водно-солевой режим, секвенциальная блокада нефрона, глифлозины, ваптаны, инотропы, вазоконстрикторы, глюкокортикостероиды, серелаксин, несиритид, альбумин

وصف الملف: application/pdf

Relation: https://bulletin.tomsk.ru/jour/article/view/4826/3214; Калюжин В.В., Тепляков А.Т., Калюжин О.В. Сердечная недостаточность. М.: Медицинское информационное агентство, 2018:376.; Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2016;18(8):891−975. DOI:10.1002/ejhf.592.; Moradi M., Daneshi F., Behzadmehr R., Rafiemanesh H., Bouya S., Raeisi M. Quality of life of chronic heart failure patients: a systematic review and meta-analysis. Heart Fail. Rev. 2020;25:993–1006. DOI:10.1007/s10741-019-09890-2.; Comín-Colet J., Martín Lorenzo T., González-Domínguez A., Oliva J., Jiménez Merino S. Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review. Health Qual Life Outcomes. 2020;18:329. DOI:10.1186/s12955-020-01566-y.; Калюжин В.В., Тепляков А.Т., Рязанцева Н.В., Беспалова И.Д., Камаев Д.Ю., Калюжина Е.В. Качество жизни больных ишемической болезнью сердца, ассоциированной с метаболическим синдромом: результаты факторного анализа. Терапевтический архив. 2012;84(12):18−22.; Goudot F.X., Thomas S., Foureur N. Patient âgé insuffisant cardiaque, qualité ou quantité de vie? Soins Gerontol. 2020;25(144):38−42. DOI:10.1016/j.sger.2020.06.009.; Калюжин В.В., Тепляков А.Т., Беспалова И.Д., Калюжина Е.В., Терентьева Н.Н., Сибирева О.Ф. и др. Прогрессирующая (advanced) сердечная недостаточность. Бюллетень сибирской медицины. 2021;20(1):129–146. DOI:10.20538/1682-0363-2021-1-129-146.; Koshy A.O., Gallivan E.R., McGinlay M., Straw S., Drozd M., Toms A.G. et al. Prioritizing symptom management in the treatment of chronic heart failure. ESC Heart Fail. 2020;7(5) 2193–2207. DOI:10.1002/ehf2.12875.; Mullens W., Damman K., Harjola V.P., Mebazaa A., BrunnerLa Rocca H.P., Martens P. et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2019;21(2):137–155. DOI:10.1002/ejhf.1369.; Boorsma E.M., Ter Maaten J.M., Damman K., Dinh W., Gustafsson F., Goldsmith S. et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat. Rev. Cardiol. 2020;17(10):641−655. DOI:10.1038/s41569-020-0379-7.; Simonavičius J., Knackstedt C., Brunner-La Rocca H.P. Loop diuretics in chronic heart failure: how to manage congestion? Heart Fail Rev. 2019;24(1):17–30. DOI:10.1007/s10741-018-9735-7.; Jardim S.I., Ramos Dos Santos L., Araújo I., Marques F., Branco P., Gaspar A., Fonseca C. A 2018 overview of diuretic resistance in heart failure. Rev. Port. Cardiol. 2018;37(11):935−945. DOI:10.1016/j.repc.2018.03.014.; Бердибеков Б.Ш. Диуретическая терапия при сердечной недостаточности: фокус на резистентность к диуретикам. Креативная кардиология. 2018;12(4):366–382. DOI:10.24022/1997-3187-2018-12-4-366-382.; Felker G.M., Ellison D.H., Mullens W., Cox Z.L., Testani J.M. Diuretic therapy for patients with heart failure: JACC state-ofthe-art review. J. Am. Coll. Cardiol. 2020;75(10):1178–1195. DOI:10.1016/j.jacc.2019.12.059.; Мареев В.Ю., Гарганеева А.А., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л., Беленков Ю.Н. и др. Экспертное мнение по применению диуретиков при хронической сердечной недостаточности. Общество специалистов по сердечной недостаточности. Кардиология. 2020;60(12):13−47. DOI:10.18087/cardio.2020.12.n1427.; Reed B.N., Devabhakthuni S. Diuretic resistance in acute decompensated heart failure: a challenging clinical conundrum. Crit. Care Nurs. Q. 2017;40(4):363–373. DOI:10.1097/CNQ.0000000000000173.; Palazzuoli A., Ruocco G., Paolillo S., Perrone Filardi P. The use of diuretics in heart failure with congestion: we can’t judge a book by its cover. ESC Heart Fail. 2019;6(6):1222–1225. DOI:10.1002/ehf2.12515.; Kazory A., Costanzo M.R. The never-ending quest for the appropriate role of ultrafiltration. Eur. J. Heart Fail. 2019;21(7):949. DOI:10.1002/ejhf.1490.; Фомин В.В., Хамхоева М.С. Резистентность к диуретикам: причины, механизмы, возможности преодоления. Фарматека. 2010;12:19–23.; Cox Z.L., Testani J.M. Loop diuretic resistance complicating acute heart failure. Heart Fail. Rev. 2020;25(1):133–145. DOI:10.1007/s10741-019-09851-9.; Suri S.S., Pamboukian S.V. Optimal diuretic strategies in heart failure. Ann. Transl. Med. 2021;9(6):517. DOI:10.21037/atm20-4600.; Дядык А.И., Куглер Т.Е., Щукина Е.В., Ракитская И.В., Зборовский С.Р., Сулиман Ю.В. Диуретическая резистентность: механизмы, лечебная тактика и профилактика. Фарматека. 2017;18:50−56.; Testani J.M., Brisco M.A., Turner J.M., Spatz E.S., Bellumkonda L., Parikh C.R. et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ. Heart Fail. 2014;7(2):261–270. DOI:10.1161/CIRCHEARTFAILURE.113.000895.; Epstein M., Lepp B.A., Hoffman D.S., Levinson R. Potentiation of furosemide by metolazone in refractory edema. Curr. Ther. Res. 1977;21:656–667.; Kumar D., Bagarhatta R. Fractional excretion of sodium and its association with prognosis of decompensated heart failure patients. J. Clin. Diagn. Res. 2015;9(4):OC01–OC03. DOI:10.7860/JCDR/2015/11532.5736.; Testani J.M., Hanberg J.S., Cheng S., Rao V., Onyebeke C., Laur O. et al. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ. Heart Fail. 2016;9(1):e002370. DOI:10.1161/CIRCHEARTFAILURE.115.002370.; Doering A., Jenkins C.A., Storrow A.B., Lindenfeld J., Fermann G.J., Miller K.F. et al. Markers of diuretic resistance in emergency department patients with acute heart failure. Int. J. Emerg. Med. 2017;10(1):17. DOI:10.1186/s12245-017-0143-x.; Ter Maaten J.M., Dunning A.M., Valente M.A., Damman K., Ezekowitz J.A., Califf R.M. et al. Diuretic response in acute heart failure-an analysis from ASCEND-HF. Am. Heart J. 2015;170(2):313–321. DOI:10.1016/j.ahj.2015.05.003.; Cox Z.L., Sarrell B.A., Cella M.K., Tucker B., Arroyo J.P., Umanath K. et al. Multinephron segment diuretic therapy to overcome diuretic resistance in acute heart failure: a single-center experience. J. Card. Fail. 2021:S1071-9164(21)00333-X. DOI:10.1016/j.cardfail.2021.07.016.; Ter Maaten J.M., Valente M.A., Damman K., Cleland J.G., Givertz M.M., Metra M. et al. Combining diuretic response and hemoconcentration to predict rehospitalization after admission for acute heart failure. Circ. Heart Fail. 2016;9(6):e002845. DOI:10.1161/CIRCHEARTFAILURE.115.002845.; Neuberg G.W., Miller A.B., O’Connor C.M., Belkin R.N., Carson P.E., Cropp A.B. et al. PRAISE Investigators. Prospective randomized amlodipine survival evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am. Heart J. 2002;44(1):31–38. DOI:10.1067/mhj.2002.123144.; Trullàs J.C., Casado J., Morales-Rull J.L., Formiga F., Conde-Martel A., Quirós R. et al. Prevalence and outcome of diuretic resistance in heart failure. Intern. Emerg. Med. 2019;14(4):529−537. DOI:10.1007/s11739-018-02019-7.; Côté J.M., Bouchard J., Murray P.T., Beaubien-Souligny W. Diuretic strategies in patients with resistance to loop-diuretics in the intensive care unit: A retrospective study from the MIMIC-III database. J. Crit. Care. 2021;65:282–291. DOI:10.1016/j.jcrc.2021.06.009.; Bellomo R., Prowle J.R., Echeverri J.E. Diuretic therapy in fluid-overloaded and heart failure patients. Contrib. Nephrol. 2010;164:153–163. DOI:10.1159/000313728.; Katz S.D. In search of euvolemia in heart failure. JACC Heart Fail. 2014;2(3):306–307. DOI:10.1016/j.jchf.2014.02.006.; Cox Z.L., Testani J.M. Loop diuretic resistance in a patient with acute heart failure. In: Tamg W.H.W., Verbrugge F.H., Mullens W., eds. Cardiorenal syndrome in heart failure. London, UK: Springer Nature, 2019:153–173.; Elhassan M.G., Chao P.W., Curiel A. The conundrum of volume status assessment: revisiting current and future tools available for physicians at the bedside. Cureus. 2021;13(5):e15253. DOI:10.7759/cureus.15253.; Watson K., Gottlieb S.S. Walking the line of euvolemia. J. Card. Fail. 2014;20(8):623−624. DOI:10.1016/j.cardfail.2014.06.356.; Sokolska J.M., Sokolski M., Zymliński R., Biegus J., Siwołowski P., Nawrocka-Millward S. et al. Distinct clinical phenotypes of congestion in acute heart failure: characteristics, treatment response, and outcomes. ESC Heart Fail. 2020;7(6):3830–3840. DOI:10.1002/ehf2.12973.; Verbrugge F.H. Editor’s choice-diuretic resistance in acute heart failure. Eur. Heart J. Acute Cardiovasc. Care. 2018;7(4):379-389. DOI:10.1177/2048872618768488.; Gupta R., Testani J., Collins S. Diuretic resistance in heart failure. Curr. Heart Fail. Rep. 2019;16(2):57−66. DOI:10.1007/s11897-019-0424-1.; Yang Y.J., Kim J., Kwock C.K. Association of genetic variation in the epithelial sodium channel gene with urinary sodium excretion and blood pressure. Nutrients. 2018;10(5):612. DOI:10.3390/nu10050612.; Kenig A., Kolben Y., Asleh R., Amir O., Ilan Y. Improving diuretic response in heart failure by implementing a patient-tailored variability and chronotherapy-guided algorithm. Front Cardiovasc. Med. 2021;8:695547. DOI:10.3389/fcvm.2021.695547.; Ellison D.H., Felker G.M. Diuretic treatment in heart failure. N. Engl. J. Med. 2017;377(20):1964–1975. DOI:10.1056/NEJMra1703100.; Hoorn E.J., Wilcox C.S., Ellison D.H. Chapter 50. Diuretics. Brenner and Rector’s the kidney eleventh edition. Elsevier, Philadelphia, PA; 2020:1708–1740.; Wilcox C.S., Testani J.M., Pitt B. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. Hypertension. 2020;76(4):1045–1054. DOI:10.1161/HYPERTENSIONAHA.120.15205.; Ravera A., Ter Maaten J.M., Metra M. Diuretic resistance and chronic heart failure. In: Tamg W.H.W., Verbrugge F.H., Mullens W., eds. Cardiorenal syndrome in heart failure. London, UK: Springer Nature, 2019:121–135. DOI:10.1007/978-3-030-21033-5_9.; Rao V.S., Planavsky N., Hanberg J.S., Ahmad T., BriscoBacik M.A., Wilson F.P. et al. Compensatory distal reabsorption drives diuretic resistance in human heart failure. J. Am. Soc. Nephrol. 2017;28(11):3414–3424. DOI:10.1681/ASN.2016111178.; Калюжин В.В., Тепляков А.Т., Черногорюк Г.Э., Калюжина Е.В., Беспалова И.Д., Терентьева Н.Н. и др. Хроническая сердечная недостаточность: синдром или заболевание? Бюллетень сибирской медицины. 2020;19(1):134–139. DOI:10.20538/1682-0363-2020-1-134–139.; Ройтберг Г.Е., Струтынский А.В. Внутренние болезни. Сердечно-сосудистая система: учеб. пособие. М.: МЕДпресс-информ, 2019:904.; McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2021;42(36):3599– 3726. DOI:10.1093/eurheartj/ehab670.; Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E. Jr., Drazner M.H. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013;62(16):e147–239. DOI:10.1016/j.jacc.2013.05.019.; Lennie T.A., Song E.K., Wu J.R., Chung M.L., Dunbar S.B., Pressler S.J., Moser D.K. Three-gram sodium intake is associated with longer event-free survival only in patients with advanced heart failure. J. Card. Fail. 2011;17(4):325–330. DOI:10.1016/j.cardfail.2010.11.008.; Billingsley H.E., Hummel S.L., Carbone S. The role of diet and nutrition in heart failure: A state-of-the-art narrative review. Prog. Cardiovasc. Dis. 2020;63(5):538−551. DOI:10.1016/j.pcad.2020.08.004.; Burgermaster M., Rudel R., Seres D. Dietary sodium restriction for heart failure: a systematic review of intervention outcomes and behavioral determinants. Am. J. Med. 2020;133(12):1391- 1402. DOI:10.1016/j.amjmed.2020.06.018.; Doukky R., Avery E., Mangla A., Collado F.M., Ibrahim Z., Poulin M.F. et al. Impact of dietary sodium restriction on heart failure outcomes. JACC Heart Fail. 2016;4(1):24–35. DOI:10.1016/j.jchf.2015.08.007.; Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., Гарганеева А.А. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(S6):8−161. DOI:10.18087/cardio.2475.; Patel Y., Joseph J. Sodium Intake and Heart Failure. Int. J. Mol. Sci. 2020;21(24):9474. DOI:10.3390/ijms21249474.; Международное руководство по сердечной недостаточности; ред. С.Дж. Болл, Р.В.Ф. Кемпбелл, Г.С. Френсис; пер. с англ. М.: Медиа Сфера, 1995:89.; Metra M., Ponikowski P., Dickstein K., McMurray J.J., Gavazzi A., Bergh C.H. et al. .Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2007;9(6–7):684−694. DOI:10.1016/j.ejheart.2007.04.003.; Bhatt A.S., Yanamandala M., Konstam M.A. For vaptans, as for life, balance is better. Eur. J. Heart Fail. 2021;23(5):751−753. DOI:10.1002/ejhf.2042.; Rodriguez M., Hernandez M., Cheungpasitporn W., Kashani K.B., Riaz I., Rangaswami J. et al. Hyponatremia in heart failure: pathogenesis and management. Curr. Cardiol. Rev. 2019;15(4):252–261. DOI:10.2174/1573403X15666190306111812.; Gunderson E.G., Lillyblad M.P., Fine M., Vardeny O., Berei T.J. Tolvaptan for volume management in heart failure. Pharmacotherapy. 2019;39(4):473−485. DOI:10.1002/phar.2239.; Yetkin E., Cuglan B., Turhan H., Ozturk S. A novel strategy to reduce the readmission rates in congestive heart failure: intermittent empirical intravenous diuretics. Cardiovasc. Endocrinol. Metab. 2020;9(2):60−63. DOI:10.1097/XCE.0000000000000200.; Buckley L.F., Carter D.M., Matta L., Cheng J.W., Stevens C., Belenkiy R.M. et al. Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. JACC Heart Fail. 2016;4(1):1−8. DOI:10.1016/j.jchf.2015.06.017.; Halatchev I.G., Wu W.C., Heidenreich P.A., Djukic E., Balasubramanian S., Ohlms K.B. et al. Inpatient versus outpatient intravenous diuresis for the acute exacerbation of chronic heart failure. Int. J. Cardiol. Heart Vasc. 2021;36:100860. DOI:10.1016/j.ijcha.2021.100860.; Verma V., Zhang M., Bell M., Tarolli K., Donalson E., Vaughn J. et al. Outpatient intravenous diuretic clinic: an effective strategy for management of volume overload and reducing immediate hospital admissions. J. Clin. Med. Res. 2021;13(4):245–251. DOI:10.14740/jocmr4499.; Buggey J., Mentz R.J., Pitt B., Eisenstein E.L., Anstrom K.J., Velazquez E.J. et al. A reappraisal of loop diuretic choice in heart failure patients. Am. Heart J. 2015;169(3):323–333. DOI:10.1016/j.ahj.2014.12.009.; Balsam P., Ozierański K., Marchel M., Gawałko M., Niedziela Ł., Tymińska A. et al. Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: Preliminary results from the randomized TORNADO trial. Cardiol. J. 2019;26(6):661−668. DOI:10.5603/CJ.a2019.0114.; Ozierański K., Balsam P., Kapłon-Cieślicka A., Tymińska A., Kowalik R., Grabowski M. et al. Comparative analysis of longterm outcomes of torasemide and furosemide in heart failure patients in heart failure registries of the European Society of Cardiology. Cardiovasc. Drugs Ther. 2019;33(1):77−86. DOI:10.1007/s10557-018-6843-5.; Verbrugge F.H., Martens P., Ameloot K., Haemels V., Penders J., Dupont M. et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur. J. Heart Fail. 2019;21(11):1415–1422. DOI:10.1002/ejhf.1478.; Gill D., Gadela N.V., Azmeen A., Jaiswal A. Usefulness of acetazolamide in the management of diuretic resistance. Proc. (Bayl. Univ. Med. Cent.). 2020;34(1):169–171. DOI:10.1080/08998280.2020.1830332.; Testani J.M., Chen J., McCauley B.D., Kimmel S.E., Shannon R.P. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265–272. DOI:10.1161/CIRCULATIONAHA.109.933275.; Brisco M.A., Zile M.R., Hanberg J.S., Wilson F.P., Parikh C.R., Coca S.G. et al. Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: insights from the DOSE trial. J. Card. Fail. 2016;22:753–760. DOI:10.1016/j.cardfail.2016.06.423.; Gheorghiade M., Vaduganathan M., Ambrosy A., Böhm M., Campia U., Cleland J.G. et al. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail. Rev. 2013;18(2):107–122. DOI:10.1007/s10741-012-9315-1.; Peri-Okonny P.A., Mi X., Khariton Y., Patel K.K., Thomas L., Fonarow G.C. et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. JACC Heart Fail. 2019;7(4):350–358. DOI:10.1016/j.jchf.2018.11.011.; Martín-Pérez M., Michel A., Ma M., García Rodríguez L.A. Development of hypotension in patients newly diagnosed with heart failure in UK general practice: retrospective cohort and nested case-control analyses. BMJ Open. 2019;9(7):e028750. DOI:10.1136/bmjopen-2018-028750.; Cautela J., Tartiere J.M., Cohen-Solal A., Bellemain-Appaix A., Theron A., Tibi T. et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur. J. Heart Fail. 2020;22(8):1357–1365. DOI:10.1002/ejhf.1835.; Crespo-Leiro M.G., Metra M., Lund L.H., Milicic D., Costanzo M.R., Filippatos G. et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2018;20(11):1505−1535. DOI:10.1002/ejhf.1236.; Tariq S., Aronow W.S. Use of inotropic agents in treatment of systolic heart failure. Int. J. Mol. Sci. 2015;16(12):29060– 29068. DOI:10.3390/ijms161226147.; Patel P.H., Nguyen M., Rodriguez R., Surani S., Udeani G. Omecamtiv mecarbil: a novel mechanistic and therapeutic approach to chronic heart failure management. Cureus. 2021;13(1):e12419. DOI:10.7759/cureus.12419.; Xiangli S., Lan L., Libiya Z., Jun M., Shubin J. Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance. Libyan J. Med. 2021;16(1):1973762. DOI:10.1080/19932820.2021.1973762.; Heringlake M., Alvarez J., Bettex D., Bouchez S., Fruhwald S., Girardis M. et al. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert Rev. Cardiovasc. Ther. 2021;19(4):325– 335. DOI:10.1080/14779072.2021.1905520.; Asai Y., Sato T., Kito D., Yamamoto T., Hioki I., Urata Y. et al. Combination therapy of midodrine and droxidopa for refractory hypotension in heart failure with preserved ejection fraction per a pharmacist’s proposal: a case report. J. Pharm. Health Care Sci. 2021;7(1):10. DOI:10.1186/s40780-021-00193-z.; Li S., Zhao Q., Zhen Y., Li L., Mi Y., Li T. et al. The Impact of Glucocorticoid Therapy on Guideline-Directed Medical Treatment Titration in Patients Hospitalized for Heart Failure with Low Blood Pressure: A Retrospective Study. Int. J. Gen. Med. 2021;14:6693–6701. DOI:10.2147/IJGM.S334132.; Liu C., Liu K. Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance. J. Card. Fail. 2014;20(9):625−629. DOI:10.1016/j.cardfail.2014.06.353.; Liu C., Ge N., Zhai J.L., Zhang J.X. Dexamethasone-induced diuresis is associated with inhibition of the renin-angiotensin-aldosterone system in rats. Kaohsiung J. Med. Sci. 2016;32(12):614−619. DOI:10.1016/j.kjms.2016.09.007.; Smets P.M., Lefebvre H.P., Aresu L., Croubels S., Haers H., Piron K. et al. Renal function and morphology in aged Beagle dogs before and after hydrocortisone administration. PLoS One. 2012;7(2):e31702. DOI:10.1371/journal.pone.0031702.; Batool A., Salehi N., Chaudhry S., Cross M., Malkawi A., Siraj A. Role of vasodilator therapy in acute heart failure. Cureus. 2021;13(8):e17126. DOI:10.7759/cureus.17126.; Cox Z.L., Hung R., Lenihan D.J., Testani J.M. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail. 2020;8(3):157−168. DOI:10.1016/j.jchf.2019.09.012.; Ng T.M., Goland S., Elkayam U. Relaxin for the treatment of acute decompensated heart failure: pharmacology, mechanisms of action, and clinical evidence. Cardiol. Rev. 2016;24(4):194–204. DOI:10.1097/CRD.0000000000000089.; Bani D. Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target. Drug Discov. Today. 2020;25(7):1239–1244. DOI:10.1016/j.drudis.2020.04.014.; Caprnda M., Zulli A., Shiwani H.A., Kubatka P., Filipova S., Valentova V. et al. The therapeutic effect of B-type natriuretic peptides in acute decompensated heart failure. Clin. Exp. Pharmacol. Physiol. 2020;47(7):1120–1133. DOI:10.1111/1440-1681.13290.; Wang L., Zhang Q., Liu M., Chen S., Han S., Li J. et al. Tolvaptan in reversing worsening acute heart failure: A systematic review and meta-analysis. J. Int. Med. Res. 2019;47(11):5414−5425. DOI:10.1177/0300060519882221.; Urbach J., Goldsmith S.R. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials. Ther. Adv. Cardiovasc. Dis. 2021;15:175394472097 7741. DOI:10.1177/1753944720977741.; Welch W.J. Adenosine type 1 receptor antagonists in fluid retaining disorders. Expert. Opin. Investig. Drugs. 2002;11(11):1553–1562. DOI:10.1517/13543784.11.11.1553.; Jhund P.S., Solomon S.D., Docherty K.F., Heerspink H.J.L., Anand I.S., Böhm M. et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021;143(4):298–309. DOI:10.1161/CIRCULATIONAHA.120.050391.; Griffin M., Rao V.S., Ivey-Miranda J., Fleming J., Mahoney D., Maulion C. et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142(11):1028–1039. DOI:10.1161/CIRCULATIONAHA.120.045691.; Sarzani R., Giulietti F., Di Pentima C., Spannella F. Sodium-glucose co-transporter-2 inhibitors: peculiar «hybrid» diuretics that protect from target organ damage and cardiovascular events. Nutr. Metab. Cardiovasc. Dis. 2020;30(10):1622– 1632. DOI:10.1016/j.numecd.2020.05.030.; Delanaye P., Scheen A.J. The diuretic effects of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection. Diabetes Metab. 2021;47(6):101285. DOI:10.1016/j.diabet.2021.101285.; Lee T.H., Kuo G., Chang C.H., Huang Y.T., Yen C.L., Lee C.C. et al. Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: an updated systematic review and meta-analysis. PLoS One. 2021;16(12):e0260312. DOI:10.1371/journal.pone.0260312.; Kitsios G.D., Mascari P., Ettunsi R., Gray A.W. Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis. J. Crit. Care. 2014;29(2):253–259. DOI:10.1016/j.jcrc.2013.10.004.; Mahmoodpoor A., Zahedi S., Pourakbar A., Hamishehkar H., Shadvar K., Asgharian P. et al. Efficacy of furosemide-albumin compared with furosemide in critically ill hypoalbuminemia patients admitted to intensive care unit: a prospective randomized clinical trial. Daru. 2020;28(1):263–269. DOI:10.1007/s40199-020-00339-8.; Urban S., Błaziak M., Biegus J., Zymliński R. Ultrafiltration in acute heart failure: current knowledge and fields for further research. Adv. Clin. Exp. Med. 2021;30(7):737−746. DOI:10.17219/acem/135347.; Prins K.W., Wille K.M., Tallaj J.A., Tolwani A.J. Assessing continuous renal replacement therapy as a rescue strategy in cardiorenal syndrome 1. Clin. Kidney J. 2015;8(1):87−92. DOI:10.1093/ckj/sfu123.; Shi X., Bao J., Zhang H., Wang H., Li L., Zhang Y. Patients with high-dose diuretics should get ultrafiltration in the management of decompensated heart failure: a meta-analysis. Heart Fail. Rev. 2019;24(6):927−940. DOI:10.1007/s10741-019-09812-2.; Morales R.O., Barbosa F., Farre N. Peritoneal dialysis in heart failure: focus on kidney and ventricular dysfunction. Rev. Cardiovasc. Med. 2021;22(3):649−657. DOI:10.31083/j.rcm2203075.; Chionh C.Y., Clementi A., Poh C.B., Finkelstein F.O., Cruz D.N. The use of peritoneal dialysis in heart failure: A systematic review. Perit. Dial. Int. 2020;40(6):527−539. DOI:10.1177/0896860819895198.; Yazdanyar A., Sanon J., Lo K.B., Joshi A.M., Kurtz E., Saqib M.N. et al. Outcomes with ultrafiltration among hospitalized patients with acute heart failure (from the national inpatient sample). Am. J. Cardiol. 2021;142:97–102. DOI:10.1016/j.amjcard.2020.11.041.; Rajapreyar I., Kumar S., Rao R.A. Ambulatory advanced heart failure patients: timing of mechanical circulatory support - delaying the inevitable? Curr. Opin. Cardiol. 2021;36(2):186– 197. DOI:10.1097/HCO.0000000000000831.; Lombardi C.M., Cimino G., Pellicori P., Bonelli A., Inciardi R.M., Pagnesi M. et al. Congestion in patients with advanced heart failure: assessment and treatment. Heart Fail. Clin. 2021;17(4):575–586. DOI:10.1016/j.hfc.2021.05.003.; Antonides C.F.J., Schoenrath F., de By T.M.M.H., Muslem R., Veen K., Yalcin Y.C. et al. EUROMACS investigators. Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study. ESC Heart Fail. 2020;7(3):1085–1094. DOI:10.1002/ehf2.12629.; Griffin M., Soufer A., Goljo E., Colna M., Rao V.S., Jeon S. et al Real world use of hypertonic saline in refractory acute decompensated heart failure: a U.S. center’s experience. JACC Heart Fail. 2020;8(3):199–208. DOI:10.1016/j.jchf.2019.10.012.; Covic A., Copur S., Tapoi L., Afsar B., Ureche C., Siriopol D. et al. Efficiency of hypertonic saline in the management of decompensated heart failure: a systematic review and meta-analysis of clinical studies. Am. J. Cardiovasc. Drugs. 2021;21(3):331–347. DOI:10.1007/s40256-020-00453-7.; Birch F., Boam E., Parsons S., Ghosh J., Johnson M.J. ‘Subcutaneous furosemide in advanced heart failure: service improvement project’. BMJ Support Palliat. Care. 2021:bmjspcare-2020-002803. DOI:10.1136/bmjspcare-2020-002803.; López-Vilella R., Sánchez-Lázaro I., Husillos Tamarit I., Monte Boquet E., Núñez Villota J., Donoso Trenado V. et al. Administration of subcutaneous furosemide in elastomeric pump vs. oral solution for the treatment of diuretic refractory congestion. High Blood Press. Cardiovasc. Prev. 2021;28(6):589−596. DOI:10.1007/s40292-021-00476-4.; Acar S., Sanli S., Oztosun C., Afsar B., Sag A.A., Kuwabara M. et al. Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review. Int. Urol. Nephrol. 2021;53(9):1839–1849. DOI:10.1007/s11255-020-02704-7.; Voors A.A., Kremer D., Geven C., Ter Maaten J.M., Struck J., Bergmann A. et al. Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur. J. Heart Fail. 2019;21(2):163–171. DOI:10.1002/ejhf.1366.; Liu W., Yan J., Pan W., Tang M. Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system. Ann. Transl. Med. 2020;8(5):243. DOI:10.21037/atm.2020.02.07.; Ma Z., Song J.J., Martin S., Yang X.C., Zhong J.C. The Elabela-APJ axis: a promising therapeutic target for heart failure. Heart Fail Rev. 2021;26(5):1249–1258. DOI:10.1007/s10741-020-09957-5.; Fudim M., Ganesh A., Green C., Jones W.S., Blazing M.A., DeVore A.D. et al. Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. Eur. Heart J. 2018;39(48):4255−4256. DOI:10.1093/eurheartj/ehy682.; Fudim M., Ponikowski P.P., Burkhoff D., Dunlap M.E., Sobotka P.A., Molinger J. et al. Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. Eur. J. Heart Fail. 2021;23(7):1076–1084. DOI:10.1002/ejhf.2196.; Козловская Н.Л. Низкомолекулярные гепарины в практике нефролога. Клиническая нефрология. 2011;1:15– 22.; Targonski R., Sadowski J., Cyganski P.A. Impact of anticoagulation on the effectiveness of loop diuretics in heart failure with cardiorenal syndrome and venous thromboembolism. Blood Coagul Fibrinolysis. 2014;25(2):180–182. DOI:10.1097/MBC.0000000000000012.; Pugliese N.R., Fabiani I., Conte L., Nesti L., Masi S., Natali A. et al. Persistent congestion, renal dysfunction and inflammatory cytokines in acute heart failure: a prognosis study. J. Cardiovasc. Med. (Hagerstown). 2020;21(7):494−502. DOI:10.2459/JCM.0000000000000974.; Fu K., Hu Y., Zhang H., Wang C., Lin Z., Lu H. et al. Insights of worsening renal function in type 1 cardiorenal syndrome: from the pathogenesis, biomarkers to treatment. Front. Cardiovasc. Med. 2021;8:760152. DOI:10.3389/fcvm.2021.760152.; Тепляков А.Т., Болотская Л.А., Степачева Т.А., Карман Н.В., Рыбальченко Е.В., Шилов С.Н. и др. Супрессивное влияние рекомбинантного иммуномодулятора ронколейкина на уровень провоспалительных цитокинов, аутоантител к кардиолипину в крови и сердечную недостаточность. Кардиология. 2008;48(8):34−40.; Reina-Couto M., Pereira-Terra P., Quelhas-Santos J., Silva-Pereira C., Albino-Teixeira A., Sousa T. Inflammation in human heart failure: major mediators and therapeutic targets. Front Physiol. 2021;12:746494. DOI:10.3389/fphys.2021.746494.; https://bulletin.tomsk.ru/jour/article/view/4826

الاتاحة: https://bulletin.tomsk.ru/jour/article/view/4826
https://doi.org/10.20538/1682-0363-2022-2-152-167